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CHAPTER I 
 
 
INTRODUCTION 
 
 
Sleep and immune interactions 
Chronic insufficient sleep is linked to inflammation, metabolic syndrome, 
cardiovascular disease, increased sensitivity to pain stimuli, fatigue, excessive 
daytime sleepiness, and impaired cognitive and physical performance.  Symptoms of 
these pathologies and conditions are associated with increased levels of 
endogenous pro-inflammatory cytokines and can be experimentally elicited by 
peripheral or central exogenous administration of these cytokines (Dantzer, 2001; 
Imeri and Opp, 2009).  Conversely, inhibition of inflammatory immunomodulators 
attenuates many sleep-loss associated symptoms.  Additionally, reduction of 
endogenous expression of cytokines, whether in mutant mice or by use of soluble 
receptors, antibodies, or receptor antagonists, inhibits spontaneous sleep [reviewed 
by (Imeri and Opp, 2009; Krueger et al., 2008; Krueger, 2012)].  There is a wealth of 
evidence indicating that cytokines are also involved in physiological sleep regulation 
and that their amplification during pathology is causative of characteristic sleep 
disturbances associated with many pathological states (Krueger et al., 2001; Imeri 
and Opp, 2009; Krueger, 2012).  Indeed, the brain, including regions associated with 
                                                          
* Portions of this chapter were adapted from a previous publication: Ingiosi AM, Opp MR, Krueger JM 
(2013) Sleep and immune function: glial contributions and consequences of aging. Curr Opin 
Neurobiol 23:806-811. 
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the regulation of sleep-wake behavior, produces and is responsive to cytokines 
(Imeri and Opp, 2009; Krueger et al., 2008; Dantzer, 2009).  Furthermore, neuronal 
activity upregulates pro-inflammatory cytokines in brain regions implicated in sleep 
regulation (Hallett et al., 2010; Churchill et al., 2008).  Impaired sleep also affects 
adaptive immune responses.  Sleep deprivation attenuates antibody responses to 
vaccine (Lange et al., 2003; Spiegel et al., 2002), whereas good sleep imparts long-
lasting immunoenhancing effects (Lange et al., 2011; Besedovsky et al., 2012).   
Moreover, sleep is a profound regulator of cellular immunity and formation of 
immunological memory critical for adaptive responses to immune challenges 
[reviewed by (Besedovsky et al., 2012)]. 
The Centers for Disease Control and Prevention declared insufficient sleep a 
public health epidemic (Centers for Disease Control and Prevention, 2014).  
Approximately 50 – 70 million American adults have a disorder of sleep or 
wakefulness.  Sleep deficiency is associated with greater propensity to chronic 
illness, reduced quality of life, impaired cognition, and even increased mortality.  
Moreover, upwards of 100 billion dollars in direct medical costs associated with the 
evaluation and treatment of sleep disorders are spent every year (Committee on 
Sleep Medicine and Research, 2006).  Whereas it is imperative to disseminate the 
importance of good sleep hygiene, investigation of mechanisms underlying sleep-
immune interactions is imperative for determining effective therapeutic interventions 
to improve quality of life and decrease the economic burden in an increasingly 24-
hour society. 
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Although we acquired substantial insight into sleep and immune system 
interactions during the last 30 years, the cellular substrates for these interactions are 
less well understood.  Most of what we know regarding central nervous system 
(CNS)-mediate processes is founded on neuron-centric studies.  However, 
understanding the role of glia in sleep and immune system function is crucial 
because research has started to shift the traditional view of these cells as passive 
constituents of the CNS to active contributors capable of mediating behavior (see 
below).  This chapter highlights the contributions of the pro-inflammatory cytokine 
interleukin-1β (IL-1) to sleep and immune responses as well as recent findings 
implicating a role for astrocytes in sleep and immune function. 
 
IL-1 and immune function 
An immunomodulator widely known to mediate sleep and immune 
interactions is the pro-inflammatory cytokine IL-1.  IL-1 is an endogenous pyrogen 
that is upregulated during innate immune responses to facilitate fever and create a 
less hospitable environment for invading pathogens.  Central IL-1 expression is 
elevated in acute pathologies such as stroke and traumatic brain injury as well as 
neurodegenerative disorders like Alzheimer’s disease and multiple sclerosis (Allan, 
2003).  Administration of IL-1 during the course of these pathologies can exacerbate 
centrally-mediated immune responses, whereas inhibition of IL-1 limits the 
detrimental effects (Rothwell and Luheshi, 2000; Allan, 2003).  IL-1 activity 
stimulates the production of several secondary mediators including chemokines, 
growth factors, and prostaglandins as well as other cytokines.  The effects of IL-1 on 
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sleep and fever, for example, are mediated, in part, by IL-6 (Olivadoti and Opp, 
2008). 
The mature, 17-kDa form of IL-1 is synthesized from the inactive, 31-kDa 
precursor, pro-IL-1, by caspase-1 (Dinarello, 1994; Thornberry et al., 1992).  IL-1 
exerts its effects through interleukin-1 receptor 1 (IL1R1) (Sims et al., 1993; O'Neill 
and Dinarello, 2000).  Signal transduction via the IL-1 / IL1R1 complex requires the 
assistance of the adapter protein IL-1 receptor accessory protein (IL-1AcP) (Wesche 
et al., 1997; Greenfeder et al., 1995).  IL-1 receptors are expressed in the CNS by 
neurons, astrocytes, oligodendrocytes, and endothelial cells (Cunningham, Jr. and 
DeSouza, 1993; Smith et al., 2009; Basu et al., 2004; Parnet et al., 1994).  
Furthermore, neurons and glia produce IL-1 in response to immune challenges 
(Bartfai and Schultzberg, 1993; Baumann et al., 1993; Dong and Benveniste, 2001).  
Although IL-1 stimulates its own synthesis (Dinarello et al., 1987; Dinarello, 
1988), the IL-1 system encompasses inherent negative regulatory mechanisms.  
IL1R type II (IL1R1II) is a decoy receptor that binds IL-1 but lacks a cytoplasmic 
signaling domain (McMahan et al., 1991; Colotta et al., 1994).  Indeed, inhibition of 
IL1RII potentiates IL-1-mediated behavioral responses (Cremona et al., 2002; 
Cremona et al., 1998).  IL-1 activity is also modulated by the naturally occurring IL-1 
receptor antagonist (IL-1ra) that competitively binds to IL1R1 (Hannum et al., 1990).  
Administration or overexpression of IL-1ra confers neuroprotection from central 
infarct (Touzani et al., 1999).  Additional modulation of IL-1 activity is provided by a 
brain-specific isoform of the accessory protein known as IL-1AcPb (Smith et al., 
2009).  Inhibition of IL-1AcPb exacerbates responses to lipopolysaccharide (LPS) 
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(Taishi et al., 2012), a component of Gram-negative bacterial cell walls that induces 
inflammatory immune challenges via cytokine production.  Finally, IL-1 cannot pass 
freely across the blood-brain barrier (BBB), but instead shuttles across the BBB via a 
self-inhibitable, saturable transport mechanism (Banks et al., 1991).     
 
IL-1 and sleep 
IL-1 is an important mediator of physiological and pathological sleep-wake 
behavior.  This cytokine is also one of few substances classified as an endogenous 
sleep regulatory substance (SRS).  The distinction of SRS is assigned if several 
criteria are met, including 1) expression of the substance fluctuates with propensity 
for sleep, 2) time spent in sleep is sensitive to exogenous administration or inhibition 
of the substance, and 3) the substance exerts effects on recognized sleep-wake 
circuitry (Borbely and Tobler, 1989; Krueger et al., 2001). 
In accordance with the SRS criteria, IL-1 expression follows a diurnal pattern 
that parallels sleep-wake behavior with the highest concentrations emerging during 
the sleep period (Moldofsky et al., 1986; Taishi et al., 1998; Lue et al., 1987).  
Indeed, peak oscillations of IL-1 mRNA are detected in sleep-associated brain 
regions when the occurrence of non-rapid eye movement sleep (NREMS) is greatest 
(Taishi et al., 1997).  A similar rhythm is reported for IL-1 protein in brain (Nguyen et 
al., 1998).  Circulating IL-1 also exhibits a diurnal rhythm in humans with the highest 
concentrations observed at sleep onset (Gudewill et al., 1992; Moldofsky et al., 
1986).  Consistent with the notion that SRS expression should vary with sleep 
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propensity, sleep deprivation elevates IL-1 (Mackiewicz et al., 1996; Taishi et al., 
1998).   
Central and peripheral exogenous administration of IL-1 alters sleep-wake 
behavior by increasing time spent in NREMS and suppressing rapid eye movement 
sleep (REMS) (Opp et al., 1991; Opp and Krueger, 1991; Fang et al., 1998; Olivadoti 
and Opp, 2008).  The somnogenic effects of IL-1 were first demonstrated in rabbits 
(Krueger et al., 1984) and have since been replicated in various species (Opp and 
Toth, 2003).  Pharmacological and genetic inhibition of IL-1 and IL1R1 decreases 
physiological sleep and attenuates pathological sleep responses.  For example, 
mice lacking IL1R1 exhibit less spontaneous NREMS (Fang et al., 1998). Similarly, 
administration of IL-1ra in the absence of, or prior to, IL-1 administration reduces 
time spent in NREMS (Opp and Krueger, 1991).  Furthermore, inhibition of IL-1 
following sleep deprivation attenuates subsequent compensatory sleep responses 
(Opp and Krueger, 1994). 
IL-1 exerts its effects on known sleep circuitry to manifest alterations in sleep-
wake behavior (Alam et al., 2004; Brambilla et al., 2007; Brambilla et al., 2010; 
Breder et al., 1988).  IL-1 inhibits wake-promoting neurons while also stimulating 
sleep-promoting neurons in the preoptic nucleus, basal forebrain, and anterior 
hypothalamus to enhance the appearance of NREMS (Alam et al., 2004).  
Microinjection of IL-1 into the dorsal raphe nucleus (DRN) of the brainstem also 
increases time spent in NREMS (Manfridi et al., 2003).  IL-1-induced REMS 
suppression is manifest, in part, by inhibiting firing rates of wake-active, REM-OFF 
serotonergic neurons within the DRN via potentiation of evoked GABAergic inhibitory 
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responses (Brambilla et al., 2007; Manfridi et al., 2003).  Additionally, microinjection 
of IL-1 into the laterodorsal tegmental nucleus (LDT) of the brainstem suppresses 
REMS (Brambilla et al., 2010).  IL-1 inhibits firing rates of REM-active cholinergic 
neurons of the LDT presumably by reducing evoked glutamatergic responses 
(Brambilla et al., 2010).  Administration of IL-1 also stimulates the production of 
adenosine, a recognized SRS (Sperlagh et al., 2004; Zhu et al., 2006).  Adenosine 
exerts inhibitory effects on wake-promoting basal forebrain neurons (Basheer et al., 
2004).  Collectively, these findings demonstrate that IL-1 regulates sleep-immune 
interactions, but the mechanisms that underlie IL-1-mediated sleep-wake behavior 
and immunomodulation require further investigation. 
 
Astrocytes and immune function 
A traditional view of astrocytes was that they played a passive, supportive 
role for neurons.  However, recent studies demonstrate that these cells are active 
contributors to complex behaviors and immune responses.  Astrocytes are the most 
abundant glial cell type in the brain.  In addition to their role as mediators of neuronal 
homeostasis, astrocytes respond rapidly to inflammation and express receptors for 
immunomodulators (Farina et al., 2007; Dong and Benveniste, 2001).  These 
characteristics indicate astrocytes are well-poised for local mediation of immune 
responses and may serve as ideal targets for early intervention.  However, studies 
investigating the role of astrocytes in innate immunity are generally lacking. 
Astrocytes express IL1R1, and in vitro studies demonstrate that application of 
IL-1 to astroglial cultures induces astrogliosis (Giulian et al., 1994), produces 
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secondary inflammatory mediators such as IL-6 (Benveniste, 1997; Pinteaux et al., 
2002), and increases adenosinergic activity (Narcisse et al., 2005).  IL-1 also impairs 
the homeostatic function of astrocytes by inhibiting glutamatergic uptake, thereby 
increasing the propensity for neurotoxicity.  This effect is abolished by administration 
of IL-1ra (Hu et al., 2000).  Furthermore, astrocytes maintain functional integrity of 
the BBB which serves to limit the passage of blood-borne substances to the CNS 
(Bush et al., 1999).  Astroglial end-feet surround the cerebrovasculature, and IL-1 
activation of astrocytes compromises the cellular junctions that comprise the BBB 
(Chaitanya et al., 2011). 
IL-1 signaling in astrocytes primarily triggers the classical pathway that 
induces nuclear factor-κB (NF-κB)-mediated transcription of inflammatory mediators 
(Parker et al., 2002).  Astroglial signaling is attenuated by IL-1ra as well as by 
genetic ablation of IL1R1 (Parker et al., 2002) and IL-1AcP (Zetterstrom et al., 
1998).  Furthermore, selective inhibition of NF-κB in astrocytes facilitates functional 
recovery and reduces lesion volume and cytokine expression following spinal cord 
injury (Brambilla et al., 2005).  Although these studies implicate astrocytes as active 
contributors of immune responses, much of our current understanding regarding 
astroglial immune contributions derives from in vitro studies.  In vivo investigations of 
astroglial functions are needed to fully elucidate mechanisms of CNS-mediated 
processes. 
 
Astrocytes and sleep 
Thirty years ago, astrocytes were identified as a source of sleep regulatory 
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substances.  Centrally administered IL-1 derived from astroglial cell cultures 
increased NREMS in rats (Tobler et al., 1984).  However, until recently, few studies 
explored astroglial contributions to sleep-wake behavior.  Current findings now 
demonstrate astrocytes play a role in sleep homeostasis.  Selectively inhibiting 
astrocyte gliotransmission via conditional astrocyte-specific expression of the 
SNARE domain of synaptobrevin II (dnSNARE) in mice reduces 
electroencephalographic (EEG) slow wave delta activity during NREMS, a traditional 
measure of sleep pressure (Halassa et al., 2009).  Inhibition of vesicular release 
from astrocytes also attenuates the compensatory increase of NREMS and cognitive 
deficits typically observed subsequent to 6 h of sleep deprivation (Halassa et al., 
2009).  These data suggest astrocytic gliotransmission contributes to the modulation 
of sleep need.  
Because impaired gliotransmission of astrocytes results in reduced sleep 
pressure, studies have turned to astrocyte-derived adenosine as a potential 
molecular substrate of this effect.  Adenosine accumulates in brain with increasing 
time awake (Schmitt et al., 2012), and extracellular elevation of adenosine 
concentrations is astrocyte dependent (Schmitt et al., 2012; Pascual et al., 2005).  
Indeed, inhibition of the adenosine 1 receptor (A1R) in wild type mice recapitulates 
the reductions in baseline EEG slow wave activity and attenuated responses to 
sleep deprivation observed in gliotransmission-impaired dnSNARE mice (Halassa et 
al., 2009; Florian et al., 2011).  Conditional CNS A1R knockout mice also fail to 
demonstrate enhanced EEG delta power following intermittent sleep deprivation 
(Bjorness et al., 2009).  Consistent with the notion that the A1R mediates sleep 
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need, chronic sleep restriction increases A1R mRNA expression in the wake-
promoting basal forebrain in rats (Kim, 2012), but not in the sleep-promoting 
hypothalamic regions of mice (Zielinski et al., 2012).  Taken together, these findings 
introduce an active role for astrocytes in sleep homeostasis.  Continued investigation 
of astroglial contributions to sleep-wake behavior is crucial to understanding sleep 
regulatory mechanisms as well as determining the elusive function(s) of sleep. 
 
Specific aims 
The overall objective of the project described here was to determine a role for 
neuronal-glial interactions in sleep-wake behavior and immunomodulation.  To 
accomplish this objective, we engineered two transgenic mouse lines that express 
IL1R1 only in the CNS and selectively on neurons or astrocytes.  These mice 
express murine IL1R1 cDNA under transcriptional control of the neuron-specific 
enolase (NSE) or the human glial fibrillary acidic protein (gfa2) promoters.  The 
transgenes were bred onto a genetic background lacking central and peripheral 
endogenous IL1R1 expression.  Those mice with selective neuronal expression of 
IL1R1 are referred to as NSE-IL1R1, and mice expressing IL1R1 selectively on 
astrocytes are called GFAP-IL1R1. 
The central hypothesis that neuronal-glial interactions, mediated by cytokines, 
contribute to altered sleep-wake behavior during immune challenge was tested 
within the context of the following aims: (1) to determine the roles of neurons and 
astrocytes in physiological sleep-wake behavior, (2) to determine the relative 
contribution of neurons and astrocytes in mediating responses to cytokines; and (3) 
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to compare neuronal- and astroglial-driven responses to systemic immune 
challenge.  To address Aim 1, transgenic sleep-wake phenotypes were 
characterized under baseline conditions and in response to sleep deprivation via 
EEG recordings in Chapter II.  Chapter III (Aim 2) describes the relative roles of 
neurons and astrocytes in sleep and immunomodulation in response to central 
immune challenge with intracerebroventricular administration of IL-1.  Responses to 
IL-1 were assessed via EEG determination of sleep-wake behavior and 
quantification of cytokine expression in brain tissue as well as in neuronal and 
astroglial cell cultures.  Finally, in Chapter IV (Aim 3), CNS modulation of behavioral 
and inflammatory responses to systemic immune challenge was investigated via 
peripheral injection of LPS in transgenic and wild type mice.  As in Chapter III, EEG 
analyses and cytokine quantification in brain tissue were performed to determine 
effects of LPS on sleep and immunomodulation, respectively.  The systematic and 
selective examination of neuronal- and astroglial-mediated cytokine activity detailed 
in later chapters will aid to expand our understanding of cellular and molecular 
contributions to sleep and immune interactions.  
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CHAPTER II 
 
 
SPONTANEOUS SLEEP AND SLEEP DEPRIVATION RESPONSES OF MICE 
EXPRESSING INTERLEUKIN-1 RECEPTOR 1 SELECTIVELY ON 
 NEURONS OR ASTROCYTES 
 
 
Abstract 
Interactions between sleep and immune function are bidirectional.  
Interleukin-1β (IL-1) is a pro-inflammatory cytokine that regulates sleep.  However, 
the cellular substrates that mediate IL-1 regulation of sleep and immune interactions 
are not fully elucidated.  To this end, we engineered two transgenic mouse lines that 
express interleukin-1 receptor 1 (IL1R1) only in the central nervous system and 
selectively on neurons or astrocytes via transcriptional control of the neuron-specific 
enolase (NSE) or human glial fibrillary acidic protein (gfa2) promoters, respectively. 
Animals with selective neuronal IL1R1 expression are referred to as NSE-IL1R1, 
and mice expressing IL1R1 on astrocytes are called GFAP-IL1R1.  Spontaneous 
sleep and temperature phenotypes were determined in transgenic and wild type 
(WT) mice via electroencephalographic recordings and brain temperature 
measurements.  Under baseline conditions, NSE-IL1R1 and GFAP-IL1R1 mice 
spend a comparable amount of time in non-rapid eye movement sleep (NREMS) but 
exhibit more rapid eye movement sleep (REMS) compared to WT.  Transgenic mice 
also have reduced theta power in REMS, enhanced NREM delta power, and lower 
brain temperatures compared to WT mice.  In response to 6 h of sleep deprivation, 
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transgenic mice sleep the same amount as WT mice but sleep is more consolidated.  
Additionally, the NREM delta power response is impaired in NSE-IL1R1 animals 
following sleep deprivation.  These data suggest that neuronal- and astroglial-
specific IL1R1 expression contributes to the modulation of spontaneous sleep and 
temperature.  Furthermore, astroglial IL1R1 activity may contribute to homeostatic 
responses to sleep deprivation. 
 
Introduction 
The reciprocal interactions between sleep and immune function are 
extensively studied.  We now know that insufficient sleep alters immune function and 
immune activation alters sleep [reviewed by (Imeri and Opp, 2009; Besedovsky et 
al., 2012; Krueger et al., 2011)].  Interleukin-1β (IL-1) is a well-characterized pro-
inflammatory cytokine that plays critical roles in host defense and serves as a mutual 
mediator of sleep and immune responses. 
Although IL-1 is commonly associated with pathological states, this cytokine 
is also involved in the regulation of physiological sleep.  The diurnal peak of IL-1 is 
concurrent with the sleep period while lower levels are in accordance with waking 
hours (Moldofsky et al., 1986; Taishi et al., 1998; Lue et al., 1987).  Central 
administration of IL-1 increases non-rapid eye movement sleep (NREMS) and 
suppresses rapid eye movement sleep (REMS) (Opp et al., 1991; Olivadoti and 
Opp, 2008), and these effects are attenuated by inhibition of IL-1 activity (Opp and 
Krueger, 1991; Imeri et al., 1993; Imeri and Opp, 2009).  Furthermore, IL-1 exerts its 
effects on known sleep circuitry (Alam et al., 2004; Brambilla et al., 2007; Brambilla 
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et al., 2010; Breder et al., 1988).  IL-1 binds to IL-1 receptor 1 (IL1R1) present on 
neurons and astrocytes (Smith et al., 2009), and these cells also produce IL-1 
(Bartfai and Schultzberg, 1993; Baumann et al., 1993; Dong and Benveniste, 2001).  
Much of our current understanding of sleep and immune function is based on 
neuron-centric studies.  However, recent research now implicates astrocytes as 
critical, active mediators of central nervous system (CNS) processes.  Astrocytes are 
the most abundant glial cell type in the brain, are responsible for homeostasis of 
neuronal functioning, express receptors for immunomodulators, respond rapidly to 
inflammation, and have a newly demonstrated role in sleep-wake processes 
(Aschner, 1998; Farina et al., 2007; Frank, 2011; Halassa et al., 2009).  These 
qualities indicate astrocytes are poised for local mediation of immune responses and 
are important constituents of sleep-wake behavior and physiology.  However, in vivo 
investigations of astroglial contributions to CNS-mediated process and behaviors are 
recent.  Consequently, much remains to be elucidated regarding the role of 
astrocytes in sleep and immune responses.  
To further our understanding of cellular contributions to sleep and immune 
interactions in the brain, we engineered two transgenic mouse lines that express 
IL1R1 only in the CNS and selectively on neurons or astrocytes.  Although these 
mice offer a unique opportunity to dissect neuronal and astroglial roles in variety of 
processes, behaviors, and pathologies, this study focuses on sleep.  
 
Methods 
Engineering and breeding of transgenic mice 
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All protocols for creating transgenic mice were approved by the University of 
Michigan Committee on Use and Care of Animals.  Full length Il1r1 cDNA was 
generated by RT-PCR from a total RNA sample extracted from mouse liver using 
Trizol reagent.  The left primer used was 5’-ATGGAGAATATGAAAGTGCTACTGG-
3’ and the right primer was 5’-CTAGCCGAGTGGTAAGTGTGTT-3’.  The NSE-
IL1R1 transgene was constructed by excising the rat neuron-specific enolase (NSE) 
promoter [described by (Forss-Petter et al., 1990 ; Mucke et al., 1994; Race et al., 
1995; Kearney et al., 2001); gifted by Dr. Miriam Meisler, University of Michigan, Ann 
Arbor, MI, USA] using SalI and HindIII digests and ligating with the pBluescriptII SK 
vector (-).  Il1r1 cDNA was inserted into the NSE containing vector at the EcoRV 
site.  The transgene fragment for microinjection was excised with SalI and SacII 
digests. 
The GFAP-IL1R1 transgene was built in the pGfa2-cLac plasmid containing 
the promoter for human glial fibrillary acidic protein (GFAP) [described by (Brenner 
et al., 1994); gifted by Dr. Michael Brenner, University of Alabama, Birmingham, AL, 
USA].  The lacZ gene was excised via digestion with BamHI.  BglII ends were added 
to Il1r1 cDNA that was subsequently cloned into the BamHI site of the pGfa2 
plasmid.  The transgene fragment for microinjection was excised with BglII digest. 
Transgenic mice were generated by the Transgenic Animal Model Core at the 
University of Michigan via pronuclear injection of the transgenes into oocytes 
obtained from (C57BL/6 X SJL)F2 mice.  NSE-IL1R1 mice were identified via PCR 
of tail snip DNA using the forward primer 5’- GGCAAGGGAGAACCCCTTCTA-3’ and 
reverse primer 5’- AATCTCCAGCGACAGCAGAGG-3’ which produced a 433 bp 
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product.  PCR of GFAP-IL1R1 tail snip DNA used the forward primer 5’- 
AGAGCCAGAGCAGGTTGGAGA-3’ and reverse primer 5’- 
TGGGGGTCTTGCTGTCATTCT-3’ yielding a 489 bp product.  Primer pairs were 
complementary to the NSE and gfa2 promoter sequences and Il1r1 sequence. 
Transgenic founders were bred with mice null for Il1r1 and Tnfr1 genes 
(B6;129S-Tnfrsf1atm1Imx Il1r1tm1Imx/J, stock #003244, The Jackson Laboratory, Bar 
Harbor, ME). Il1r1-/-Tnfr1-/- mice were used for breeding because transgenic TNFR1 
counterparts were simultaneously engineered with the transgenic IL1R1 mice.  To 
generate transgenic IL1R1 strains null for the endogenous Il1r1 gene and wild type 
for the endogenous Tnfr1 gene, transgenic progeny of the founders were crossed 
with non-transgenic littermates (Tg(IL1R1)Il1r1+/-Tnfr1+/- x Il1r1+/-Tnfr1+/-).  Non-
transgenic progeny carrying endogenous Il1r1 and Tnfr1 (Il1r1+/+Tnfr1+/+) were used 
as wild type (WT) controls.   As per instructions of the Jackson Laboratory, mice 
were genotyped for wild type and mutant alleles of Il1r1 and Tnfr1 using custom 
primers.  Wild type Il1r1 was identified using the primer pair 5’-
GGTTTGAATGTTGGGGTTTG-3’ (forward) and 5’-CACCACCACCTGGCTACTTT-3’ 
(reverse), whereas mutant Il1r1 primer pairs were 5’-
TCTGGACGAAGAGCATCAGGG-3’ (forward) and 5’-CAAGCAGGCATCGCCATG-
3’ (reverse).  Wild type Tnfr1 was detected with the primer pair 5’-
GGATTGTCACGGTGCCGTTGAAG-3’ (forward) and 5’-
TGACAAGGACACGGTGTGTGGC-3’ (reverse), and mutant Tnfr1 used primer pairs 
5’-TGCTGATGGGGATACATCCATC-3’ (forward) and 5’-
CCGGTGGATGTGGAATGTGTG-3’ (reverse). 
24 
 
Experimental animals express IL1R1 only in the CNS and selectively on 
neurons or astrocytes.  Those mice with selective neuronal expression of IL1R1 are 
referred to as NSE-IL1R1, and mice expressing IL1R1 selectively on astrocytes are 
called GFAP-IL1R1.  Figure 2.1 (A – C) shows co-localization of IL1R1 expression 
with neuronal staining in NSE-IL1R1 mouse brain. Conversely, IL1R1 expression 
specifically co-localizes with astrocytes in GFAP-IL1R1 mouse brain (Figure 2.1, D – 
F). 
 
Animals 
During the studies, adult male WT, NSE-IL1R1, and GFAP-IL1R1 mice (20 – 
30 g, 8 – 12 weeks at time of surgery) were obtained from our breeding colony and 
individually housed in standard cages on a 12:12 h light:dark cycle at 29 ± 1ºC.  
Food and water were available ad libitum.  All procedures involving the experimental 
use of animals were approved by the University of Washington Institutional Animal 
Care and Use Committee in accordance with the US Department of Agriculture 
Animal Welfare Act and the National Institutes of Health policy on Humane Care and 
the Use of Laboratory Animals. 
 
In situ hybridization and immunofluorescence 
Mice were lightly anesthetized, euthanized via bilateral pneumothorax, and 
transcardially perfused with 10% buffered formalin.  Brains were paraffin embedded 
and cut sagittally on a sliding microtome in 10 µM sections. 
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Identification of IL1R1 in NSE-IL1R1 brain tissue was achieved via in situ 
hybridization using a digoxigenin (DIG)-labeled probe generated from murine IL1R1 
cDNA using the AmpliScribe T7-Flash Transcription Kit (ASB71110, Epicentre, 
Madison, WI, USA).  After in situ hybridization, tissue was blocked in 10% normal 
donkey serum (017-000-121, Jackson ImmunoResearch, Inc., West Grove, PA, 
USA) and incubated with anti-DIG made in sheep (11333089001, Roche Nutley, NJ, 
USA) for 1 h.  DIG was the visualized via 1 h incubation with Alexa Fluor 488 donkey 
anti-sheep (A-11015) secondary antibody.  Neurons were identified by sequential 1 
h incubations with the primary antibody mouse anti-NeuN (MAB377, EMD Millipore, 
Temecula, CA, USA) and the secondary antibody Alexa Fluor 555 donkey anti-
mouse (A-31570).  All antibody solutions were made in 1% normal donkey serum at 
a concentration of 1:500.  Secondary antibodies were purchased from Life 
Technologies (Carlsbad, CA, USA). 
IL1R1 in GFAP-IL1R1 brain sections was detected with sequential 1 h 
incubations with the primary antibody rabbit anti-IL1R1 (sc-25775, Santa Cruz 
Biotechnology, Inc., Dallas, TX, USA) and secondary antibody Alexa Fluor 555 
donkey anti-rabbit (A-31572).  Astrocytes were identified via sequential treatment 
with the primary antibody anti-GFAP made in chicken (GFAP, Aves Labs, Inc., 
Tigard, OR, USA) and the secondary antibody Alexa Fluor 488 donkey anti-chicken 
(703-545-155, Jackson ImmunoResearch, Inc.).  All antibody solutions were made in 
1% normal donkey serum at a concentration of 1:500.  Secondary antibodies were 
purchased from Life Technologies unless otherwise noted. 
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Surgical procedures 
Electroencephalographic (EEG) recordings were obtained from mice 
stereotaxically instrumented under isoflurane anesthesia with three stainless steel 
screws (MPX-0080-02P-C, Small Parts Inc., Logansport, IN, USA) and a calibrated 
10 kΩ thermistor (AB6E3-GC16KA103L, Thermometrics, Northridge, CA, USA) as 
previously described (Baracchi and Opp, 2008).  Analgesia was provided at the time 
of surgery by subcutaneous (SC) injection of buprenorphine (0.05 mg/kg) as well as 
topical application of 4% lidocaine at the incision site.  Penicillin (1,200,000 IU/kg; 
SC) and topical triple antibiotic treatment of the surgical site was also provided to 
minimize risk of infection.  Additional buprenorphine (0.03 mg/kg; SC) was 
administered 24 h post-surgery.  Animals were allowed at least seven days recovery 
prior to initiation of experimental protocols. 
 
Data acquisition 
EEG and temperature data were obtained by connecting the mice to a 
lightweight flexible tether that allowed unrestricted movement as previously 
described (Baracchi and Opp, 2008).  Cage activity was monitored by an infrared 
sensor (BioBserve, GmbH, Bonn, Germany).  Digitized EEG signals were stored as 
binary files for subsequent analysis. 
Arousal state was determined by visual inspection of the EEG, theta-to-delta 
ratio, brain temperature, and cage activity with 10 s resolution using custom software 
(ICELUS, M. Opp, University of Washington) written in LabView for Windows 
(National Instruments, Austin, Texas, USA) based on previously published criteria 
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(Opp and Krueger, 1994; Opp, 1998).  Epochs containing artifacts were excluded 
from subsequent spectral analyses.  The EEG underwent fast Fourier transformation 
(FFT) to produce power spectra between 0.5 and 30 Hz in 0.5 Hz bins as previously 
described (Baracchi and Opp, 2008).  Spectral bins within the delta () and theta  () 
bands were normalized to the total state-specific power (delta in NREMS; theta in 
REMS) summed across all frequency bins from 0.5 to 30 Hz for the 12h light and 
dark periods and expressed as a percentage of total power.  Hourly NREM delta 
power data from the light and dark periods were normalized to 12 h light and dark 
averages, respectively, derived from control conditions. 
 
Determination of sleep phenotype and responses to sleep deprivation 
After recovery from surgery and habituation to the recording environment, 48 
h of undisturbed baseline recordings beginning at light onset (LO) were obtained 
from WT (n = 7), NSE-IL1R1 (n = 8), and GFAP-IL1R1 (n = 7).  Animals were then 
subjected to 6 h sleep deprivation via gentle handling beginning at LO.  Upon 
observation of behavioral sleep cues, laboratory personnel introduced arousing 
acoustic, tactile, or novel object stimuli.  Following sleep deprivation, mice were 
allowed 18 h of undisturbed recovery sleep. 
 
Statistical analysis 
Statistical analyses were performed using SPSS for Windows (IBM 
Corporation, Armonk, NY, USA).  Data are presented as means ± standard error of 
the mean (SEM).  Between strain comparisons for baseline sleep physiology, 
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temperature, cage activity, spectral analyses, and calculated difference scores for 
sleep deprivation effects were performed in 12 h and 6 h time blocks using one-way 
analysis of variance (ANOVA) with strain (WT, NSE-IL1R1, GFAP-IL1R1) as the 
independent variable.  If statistically significant strain effects were revealed, post-hoc 
comparisons by Tukey’s HSD test were used to determine differences among 
transgenic and WT mice.  
Within strain comparisons for percentage of time in REMS and NREMS, 
normalized NREM delta power, and brain temperature were performed via a general 
linear model for repeated measures using time (hours) as the repeated measure and 
manipulation (undisturbed baseline vs. 6 h sleep deprivation) as the between-
subjects factor.  
An alpha level of p < 0.05 was accepted as indicating significant departures 
from control conditions or strain differences for all tests. 
 
Results 
Comparison of physiological sleep phenotypes and temperature 
There were no differences among strains in the percentage of time spent in 
wakefulness or NREMS during the 24 h baseline recording period (Figure 2.2).  
However, NSE-IL1R1 and GFAP-IL1R1 mice had more wake bouts during the light 
period, and GFAP-IL1R1 mice also had more wake bouts during the dark period.  
Wake bouts during the dark period were shorter in GFAP-IL1R1 mice than in WT 
animals.  NSE-IL1R1 mice had more bouts of NREMS during the light period that 
were of shorter duration than those of WT mice.  Both transgenic lines spent more 
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time in REMS during the light period in comparison to WT counterparts.  This 
increase in REMS is due, in part, to more REM bouts.  Additionally, during the dark 
period, GFAP-IL1R1 mice had longer REM bouts than did WT mice.  Sleep of 
GFAP-IL1R1 mice is fragmented during the dark period, likely as a consequence of 
an increased number of wake bouts. 
Normalized EEG spectra obtained during NREM and REM sleep differed 
among strains (Figures 2.2 and 2.3).  NREM delta power (0.5 – 4.5 Hz) was greater 
in NSE-IL1R1 and GFAP-IL1R1 mice than in WT mice.  The REMS EEG of both 
transgenic strains contained less theta power (6.0 – 9.0 Hz) compared to WT 
counterparts, and REM theta power was reduced in GFAP-IL1R1 mice compared to 
NSE-IL1R1 animals.   
Finally, brain temperature in WT mice was higher than NSE-IL1R1 and 
GFAP-IL1R1 animals for the entire 24 h period, whereas cage activity did not differ 
among strains (Figure 2.4). 
 
Responses to 6-h sleep deprivation 
The deprivation method was effective as REMS and NREMS were virtually 
abolished for all strains of mice during this 6 h period (Figure 2.5).  During sleep 
deprivation, brain temperatures of WT and NSE-IL1R1 mice, but not GFAP-IL1R1 
mice, were significantly increased. 
There were significant increases in NREMS and REMS during the recovery 
period after deprivation ended (Figure 2.5).  Sleep deprivation induced a statistically 
significant REMS rebound in the dark period for all strains.  WT and transgenic mice 
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also exhibited a small but significant increase in NREMS during the first 6 h of 
recovery.  Although the increased time spent in NREMS was modest, this was 
accompanied by a significant elevation of NREM delta power in all strains for the 6 h 
period post-deprivation.  NSE-IL1R1 mice also exhibited a greater amount of time 
spent in NREMS in the early portion of the dark period.  Sleep deprivation had no 
effect on brain temperature in the 18 h recovery period. 
To determine if responses to sleep deprivation differed among WT and 
transgenic mice, difference scores were calculated by subtracting sleep deprivation 
values from baseline (Figure 2.6).  No strain differences were detected for the 
amount of REMS or NREMS acquired during the 18 h recovery period following 
sleep deprivation.  NSE-IL1R1 mice had significantly less NREM delta power 
compared to WT during the first 12 h post-deprivation, presumably indicating less 
restorative sleep.  However, sleep of NSE-IL1R1 and GFAP-IL1R1 mice was more 
consolidated than that of WT mice during the first 6 h of recovery as evidenced by 
fewer sleep state transitions.  Brain temperature during the recovery period did not 
differ among stains. 
 
Discussion 
Physiological sleep 
There is an abundance of data demonstrating a role for IL-1 in the regulation 
of sleep [reviewed by (Krueger et al., 2011; Imeri and Opp, 2009)], yet the 
contributions of neurons and astrocytes to sleep-wake behavior remain largely 
unknown.  This study aimed to establish a role for neurons and astrocytes in IL-1 
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regulation of sleep.  To this end, we engineered two transgenic mouse lines that 
express IL1R1 only in the CNS, and selectively on neurons (NSE-IL1R1) or 
astrocytes (GFAP-IL1R1).  During spontaneous sleep, NSE-IL1R1 and GFAP-IL1R1 
mice have more REMS during the light period that is characterized by reduced theta 
power in the EEG spectra.  NREM delta power of transgenic mice is also elevated in 
comparison to WT animals.  In response to 6 h of sleep deprivation, sleep of 
transgenic mice is more consolidated than that of WT animals.  Although the NREM 
EEG of NSE-IL1R1 mice contains less delta power.   
Previous findings demonstrate that mice lacking IL1R1 have normal REMS 
(Fang et al., 1998).  Our data suggest neuronal and astroglial IL1R1 contribute to 
REMS regulation.  Transgenic mice with IL1R1 selectively on neurons or on 
astrocytes have more REMS during the light period.  Current knowledge regarding 
the brain regions and neurotransmitters involved in mediating effects of IL-1 on 
REMS is limited.  Most studies demonstrate that IL-1 suppresses REMS (Opp et al., 
1991; Opp and Toth, 1998; Fang et al., 1998; Olivadoti and Opp, 2008; Brambilla et 
al., 2010). However, microinjection of IL-1 into the rostral margins of the laterodorsal 
tegmental nucleus adjacent to the dorsal raphe nucleus (DRN) increase REMS 
(Brambilla et al., 2010).  The DRN contains serotonergic REM-OFF neurons 
(McCarley, 2007), and IL-1 inhibits DRN serotonergic activity in vitro (Manfridi et al., 
2003; Brambilla et al., 2007).  IL-1 also induces adenosine release (Sperlagh et al., 
2004; Zhu et al., 2006), and stimulation of adenosine A1 receptors diminishes 
extracellular serotonin (Feuerstein et al., 1988; Okada et al., 1997).  Therefore, 
enhanced REMS in transgenic mice during the light period, when the diurnal 
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expression of IL-1 is greatest (Moldofsky et al., 1986; Taishi et al., 1998; Lue et al., 
1987), may be due to subsequent adenosinergic suppression of REM-OFF 
serotoninergic neurons in the DRN.   
Several studies demonstrate that REMS is generated in the brainstem which 
contains cholinergic REM-ON neurons in laterodorsal and pedunculopontine 
tegmental nuclei (LDT/PPT) [reviewed by (Brown et al., 2012)].  Microinjection of IL-
1 into the LDT reduces REMS (Brambilla et al., 2010).  Similarly, IL-1 inhibits firing 
rates of cholinergic LDT neurons in vitro.  Attenuation of cholinergic activity appears 
to be a consequence of inhibiting evoked glutamatergic responses and, thus, 
excitatory drive in cholinergic LDT neurons (Brambilla et al., 2010).  An essential 
function of astrocytes is to regulate extracellular concentrations of glutamate.  
However, IL-1 impairs astroglial glutamate uptake (Ye and Sontheimer, 1996; Hu et 
al., 2000).  Consequently, there may be an excess of glutamate in the extracellular 
space of transgenic mice due to disturbed IL-1-mediated glutamatergic dynamics of 
the tripartite synapse. This putative overabundance of glutamate may, in turn, 
stimulate cholinergic REM-ON neurons of the LDT resulting in the initiation and 
enhancement of REMS in transgenic mice during the light period.  However, 
additional experiments are necessary to determine the mechanisms of neuronal and 
astroglial modulation of REMS via IL1R1. 
In contrast to REMS, the percentage of time spent in NREMS is not altered in 
NSE-IL1R1 or GFAP-IL1R1 mice compared to WT counterparts.  Mice lacking IL1R1 
exhibit less NREMS (Fang et al., 1998), and antagonizing IL-1 with the IL-1 receptor 
antagonist (Opp and Krueger, 1991), antibodies (Opp and Krueger, 1994), or soluble 
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receptors (Imeri et al., 1993) or inhibiting its production (Imeri et al., 2006) reduces 
NREMS.  Collectively, these data demonstrate a role for IL-1 in the regulation of 
spontaneous NREMS.  Our new data suggest that selective IL1R1 expression on 
neurons or astrocytes is sufficient for spontaneous NREMS.  Although the amount of 
time spent in NREMS is unchanged in transgenic animals, NREMS architecture 
during the light period is altered in NSE-IL1R1 mice, but not in GFAP-IL1R1 mice.  
Collectively, these results implicate a role for astroglial IL1R1 in the initiation and 
maintenance of NREMS.   
The basal forebrain and preoptic areas of the anterior hypothalamus are 
primary regulatory nuclei of NREMS.  In particular, the median preoptic nucleus 
(MnPO) contains a large number of GABAergic sleep-ON/wake-OFF neurons that 
send inhibitory projections to wake-active neurons of the ascending reticular 
activating system [reviewed by (Brown et al., 2012)].  Central administration of IL-1 
in rats induces c-Fos protein expression in the MnPO with an associated increase of 
NREMS (Baker et al., 2005).  Taken together with the results of this current study, 
astroglial IL1R1 expression in the MnPO may contribute to the configuration of 
NREMS architecture.  Still, further experimentation is needed required. 
Although the amount of NREMS is normal in transgenic animals, NSE-IL1R1 
and GFAP-IL1R1 mice exhibit enhanced NREM delta power.  NREM delta power is 
widely regarded as a marker of NREMS quality or depth (Borbély, 1982).  These 
results are consistent with previous studies that demonstrate dissociation of NREMS 
delta power from time spent in NREMS (Halassa et al., 2009; Yasuda et al., 2005; 
Davis et al., 2011).  Transgenic mice also have a reduction in the REM theta peak 
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compared to WT.  Therefore, the demonstrated increase in transgenic REMS may 
be offset by attenuation of theta power.  These effects on NREM delta and REM 
theta power may be mediated, in part, by the cholinergic basal forebrain (BF).  
Inhibition of cholinergic BF neurons increases delta power and suppresses theta 
activity (Cape and Jones, 2000).  Indeed, IL-1 suppresses discharge activity of 
wake-active BF neurons (Alam et al., 2004).  Likewise, adenosine inhibits cholinergic 
and non-cholinergic neurons of the BF (Basheer et al., 2004).  Taken together, IL-1 
may influence NREMS delta and REMS theta power through inhibition of cholinergic 
neurons in the BF.  This effect may be modulated, to some extent, by adenosine.   
Furthermore, NREM delta and REM theta power may not be dependent specifically 
on neuronal or astroglial IL1R1 expression.  However, neuronal IL1R1 activity may 
contribute more prominently to REM theta power as evidenced by greater 
suppression of the theta peak in GFAP-IL1R1 mice compared to WT and NSE-
IL1R1 mice during the dark period. 
Transgenic mice have lower brain temperatures than WT animals under 
physiological conditions, a result that does not appear to be neuron- or astrocyte-
specific.  Moreover, this temperature reduction is not due to diminished cage activity.  
Thermoregulatory centers reside in the preoptic area and anterior hypothalamus.  
Stimulation of cholinergic neurons in these nuclei lowers brain temperature (Imeri et 
al., 1995; Mallick and Joseph, 1997; Takahashi et al., 2001).  Interestingly, 
hypothalamic thermoregulatory areas like the preoptic nucleus are innervated by the 
LDT/PPT (Chiba and Murata, 1985).  In view of the fact that transgenic mice have 
more REMS which may be mediated, in part, by activation of LDT/PPT cholinergic 
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neurons at least in wild type animals, it is not unreasonable to postulate that 
transgenic brain temperature reductions may be a result of enhanced stimulation of 
preoptic areas via LDT/PPT projections.   
 
6-h sleep deprivation 
Responses to sleep deprivation are similar across all strains including REMS 
rebound, transient increase in NREMS, enhanced delta power, and increased sleep 
consolidation.  Previous studies demonstrate that IL1R1 knockout mice have more 
wakefulness and less NREMS compared to wild type animals following sleep 
deprivation (Schmidt and Wisor, 2012).  NSE-IL1R1 and GFAP-IL1R1 mice do not 
differ from WT in terms of percentage of times spent in REMS, NREMS, or 
wakefulness (data not shown) after 6 h sleep deprivation.  These data suggest that 
neuronal and astroglial IL1R1 expression is sufficient for rebound sleep responses 
during the post-deprivation recovery period. 
One of the major strain differences in response to sleep deprivation is that 
transgenic mice have more consolidated sleep during the first 6 h of the recovery 
period.  This sleep consolidation is generally indicative of more efficient sleep 
[reviewed (Imeri and Opp, 2009)], and thus, transgenic mice may recover from 
insufficient sleep more quickly than WT animals.  Central IL-1 administration 
fragments sleep (Olivadoti and Opp, 2008), and sleep deprivation induces elevations 
in IL-1 (Mackiewicz et al., 1996; Taishi et al., 1998).  Therefore, IL1R1 expression 
limited to either neurons or astrocytes in transgenic mice may account for this 
increased sleep consolidation. 
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The two-process model of sleep regulation states that sleep is mediated, in 
part, by a homeostatic mechanism that increases propensity for sleep with 
increasing time awake (Borbély, 1982).  In response to sleep deprivation, NSE-
IL1R1 mice have less NREM delta power 12 h post sleep deprivation compared to 
WT.  This result suggests that the sleep homeostat in NSE-IL1R1 is less affected by 
sleep loss under these conditions.  Inhibition of gliotransmission by astrocytes 
attenuates enhancement of delta power following sleep deprivation.  This altered 
homeostatic response is due to the inhibition of astrocyte-derived adenosine which 
signals via the adenosine A1 receptor (A1R) (Halassa et al., 2009).  Furthermore, 
conditional knockout of the A1R attenuates EEG delta power responses to 
intermittent sleep deprivation (Bjorness et al., 2009).  As previously mentioned, IL-1 
increases with prolonged time awake (Mackiewicz et al., 1996; Taishi et al., 1998), 
and IL-1 induces adenosine production (Sperlagh et al., 2004; Zhu et al., 2006).  
Therefore, IL-1 signaling via astroglial IL1R1 may be modulated by the production of 
adenosine.  Additionally, lack of IL1R1 on astrocytes in NSE-IL1R1 mice could result 
in lower extracellular concentrations of adenosine, further indicating that neuronal 
IL1R1 activation may not stimulate as much adenosine release as astroglial IL1R1 
activity.  Alternatively, neuron-derived adenosine may act via mechanisms distinct 
from astroglial-derived adenosine (Lovatt et al., 2012).  
 
Conclusions 
Overall, these studies demonstrate the complexity of sleep and immune 
interactions and provide a foundational basis from which to build.  Future studies 
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may aim to identify the contributions of other cell types including microglia.  
Discerning the molecular contributions of astrocytes and other neural cells will be 
vital to understanding a variety of CNS-mediated processes and behaviors. 
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Figure 2.1: (A) In situ hybridization for IL1R1 and (B) immunofluorescent neuronal 
staining (NeuN) in NSE-IL1R1 brain tissue. (C) Merged image of IL1R1 (green) and 
NeuN (red) staining indicates IL1R1 is expressed on neurons in NSE-IL1R1 mice. 
(D) Immunofluorescent detection of IL1R1 and (E) astrocytes (GFAP) in GFAP-
IL1R1 brain tissue. (F) Merged image shows IL1R1 (red) co-localizes with astrocytes 
(green) in GFAP-IL1R1 mice. Images are 40x; scale bar = 50 µM. 
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Figure 2.2:  Sleep architecture parameters shown as 12 h averages derived from 
undisturbed baseline conditions during the light and dark periods for WT, NSE-
IL1R1, and GFAP-IL1R1 mice.  Values are means ± SEM.  Asterisk (*) indicates a 
statistical difference of p < 0.05 from WT.  Pound sign (#) denotes a statistical 
difference of p < 0.05 from NSE-IL1R1.
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Figure 2.3: State-specific, normalized EEG power spectra for WT, NSE-IL1R1, and 
GFAP-IL1R1 mice obtained during 12 h light and dark periods of 24 h undisturbed 
baseline recordings.  Spectral analyses were performed on frequencies 0.5 – 30.0 
Hz, but data depicted are limited to 0.5 – 20.0 Hz.  Spectra were normalized as a 
percentage of total power across all frequencies for specific sleep states within the 
12 h light or dark periods.  Values are plotted as means ± SEM for each frequency 
bin.  Statistical analyses were conducted on the delta (0.5 – 4.5 Hz) frequency band 
for NREMS and the theta (6.0 – 9.0 Hz) frequency band for REMS.  Double asterisk 
(**) indicates a statistical difference of p < 0.01 from WT.  Pound sign (#) denotes 
statistical difference of p < 0.05 from NSE-IL1R1.  Dark columns indicate spectra 
derived from the 12 h dark period. 
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Figure 2.4:  Brain temperature and cage activity reported as 12 h averages derived 
from undisturbed baseline conditions during the light and dark periods for WT, NSE-
IL1R1, and GFAP-IL1R1 mice.  Values are means ± SEM.  Asterisk (*) indicates a 
statistical difference of p < 0.05 from WT.  Pound sign (#) denotes a statistical 
difference of p < 0.05 from NSE-IL1R1. 
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Figure 2.5:  Percentage of recording time spent in REMS and NREMS, normalized 
NREM delta power, and brain temperature responses obtained under undisturbed 
baseline conditions (open symbols) and during and after 6 h of sleep deprivation 
(SD; filled symbols) for WT, NSE-IL1R1, and GFAP-IL1R1 mice.  Values are means 
± SEM.  Hourly data for EEG delta power were normalized to 12 h light and dark 
undisturbed baseline averages.  Statistical analyses were conducted on 6 h time 
blocks.  Asterisk (*) denotes statistical difference of p < 0.05 from undisturbed 
baseline conditions. The open and filled bars on the X-axis indicate light and dark 
periods of the light-dark cycle, respectively.  The cross-hatched portion of the open 
bar on the X-axis denotes the 6 h sleep deprivation period. 
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Figure 2.6:  Effects of 6 h of sleep deprivation shown as differences from 
undisturbed baseline conditions for percentage of recording time spent in REMS and 
NREMS, normalized NREM delta power, number of sleep state transitions, and brain 
temperature plotted in 6 h time blocks for the 18 h period following 6 h of sleep 
deprivation for WT, NSE-IL1R1, and GFAP-IL1R1 mice.  Values are means ± SEM.  
Asterisk (*) indicates statistical difference of p < 0.05 from WT.  Open and filled bars 
on the X-axis denote light and dark portions of the light-dark cycle, respectively. 
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CHAPTER III 
 
 
SELECTIVE CONTRIBUTIONS OF NEURONAL AND ASTROGLIAL 
INTERLEUKIN-1 RECEPTOR 1 TO INTERLEUKIN-1-INDUCED ALTERATIONS IN  
SLEEP AND IMMUNMODULATION 
 
 
Abstract 
Immune challenges alter central nervous system (CNS)-mediated processes 
and behaviors including immunomodulation and sleep.  Interleukin-1β (IL-1) is a pro-
inflammatory cytokine that mediates sleep and immune interactions.  However, the 
mechanisms by which the CNS regulates behavior and physiology during immune 
responses are not fully understood.  To this end, we used two transgenic mouse 
lines that express interleukin-1 receptor 1 (IL1R1) only in the CNS and selectively on 
neurons (NSE-IL1R1) or astrocytes (GFAP-IL1R1).  Mice were instrumented with 
cranial electroencephalographic electrodes, a thermistor, and a guide cannula 
positioned in the lateral ventricle.  Intracerebroventricular injection of 50 ng IL-1 
suppressed rapid eye movement sleep (REMS), increased non-rapid eye movement 
sleep (NREMS), decreased NREM delta power, and induced fever in wild type (WT) 
mice.  Conversely, IL-1 did not alter sleep or temperature of NSE-IL1R1 or GFAP-
IL1R1 mice.  Likewise, IL-1 elevated IL-6 expression in brain tissue of WT mice but 
failed to do so in transgenic animals.  However, de novo IL-1 was detected in brain 
tissue of all mouse strains in response to exogenous IL-1 administration.  
Furthermore, IL-1 induced IL-6 production in NSE-IL1R1 neuronal and GFAP-IL1R1 
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astroglial cell cultures.  Collectively, these data suggest selective IL1R1 expression 
on neurons or astrocytes is not sufficient for sleep, temperature, or normal in vivo 
immunomodulatory responses to central administration of IL-1. 
 
Introduction 
Interactions between sleep and immune function are bidirectional.  Insufficient 
sleep is associated with elevated expression of inflammatory mediators.  Likewise, 
immune challenges alter sleep-wake behavior [reviewed by (Imeri and Opp, 2009; 
Besedovsky et al., 2012; Krueger et al., 2011)].  Interleukin-1β (IL-1) is pro-
inflammatory cytokine that mediates interactions between sleep and immune 
function. 
Central administration of IL-1 induces febrile responses, increases non-rapid 
eye movement sleep (NREMS), and suppresses rapid eye movement sleep (REMS) 
(Olivadoti and Opp, 2008; Opp et al., 1991).  IL-1-induced alterations in sleep and 
temperature are attenuated by pharmacological and genetic manipulations of IL-1 
activity (Opp and Krueger, 1991; Imeri et al., 1993; Fang et al., 1998).  IL-1 exerts its 
effects via IL-1 receptor 1 (IL1R1) expressed on neurons and astrocytes (Smith et 
al., 2009), and these cells also produce IL-1 (Bartfai and Schultzberg, 1993; 
Baumann et al., 1993; Dong and Benveniste, 2001).  
Traditionally, astrocytes were relegated to passive constituents of the central 
nervous system (CNS).  However, recent findings demonstrate these cells are active 
mediators of CNS processes.  Astrocytes express receptors for immunomodulators, 
rapidly respond to inflammation, and modulate sleep homeostasis (Aschner, 1998; 
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Farina et al., 2007; Frank, 2011; Halassa et al., 2009).  The objective of this study 
was to determine a role for neurons and astrocytes in sleep and immune 
interactions.  To this end, we evaluated sleep and immunomodulatory responses to 
IL-1 in two transgenic mouse lines that express IL1R1 only in the CNS and 
selectively on neurons or astrocytes. Understanding the contributions of astrocytes 
to sleep-immune interactions is important for elucidating the mechanisms that 
govern a variety of CNS-mediated processes and behaviors. 
 
Methods 
Animals 
Transgenic and wild type (WT) mice used for these studies were engineered 
by our lab as previously described in Chapter II.  Briefly, transgenic mice were 
designed on background lacking IL1R1.  IL1R1 was rescued by driving expression to 
neurons with the rat neuron specific enolase [NSE; (Forss-Petter et al., 1990)] 
promoter or to astrocytes via the human glial fibrillary acidic protein [gfa2; (Brenner 
et al., 1994)] promoter.  Therefore, mice express IL1R1 only in the CNS and 
selectively on neurons or astrocytes.   Mice expressing IL1R1 specifically on 
neurons are called NSE-IL1R1, whereas mice with astroglial localized expression of 
IL1R1 are referred to as GFAP-IL1R1.  Heterozygous Il1r1+/- non-transgenic 
littermates were mated to generate mice homozygous positive for endogenous Il1r1 
(Il1r1+/+).  These homozygous mice were used as wild type (WT) controls for NSE-
IL1R1 and GFAP-IL1R1 mice.   
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During the studies, adult male WT, NSE-IL1R1, and GFAP-IL1R1 mice (20 – 
30 g, 8 – 12 weeks at time of surgery) were obtained from our breeding colony and 
individually housed in standard cages on a 12:12 h light:dark cycle at 29 ± 1ºC.  
Food and water were available ad libitum.  All procedures involving the experimental 
use of animals were approved by the University of Washington Institutional Animal 
Care and Use Committee in accordance with the US Department of Agriculture 
Animal Welfare Act and the National Institutes of Health policy on Humane Care and 
the Use of Laboratory Animals. 
 
Surgical procedures 
Mice used for electroencephalographic (EEG) recordings were stereotaxically 
instrumented under isoflurane anesthesia with three stainless steel screws (MPX-
0080-02P-C, Small Parts Inc., Logansport, IN, USA) and a calibrated 10 kΩ 
thermistor (AB6E3-GC16KA103L, Thermometrics, Northridge, CA, USA) as 
previously described (Baracchi and Opp, 2008). 
Mice receiving intracerebroventricular (i.c.v.) injections were stereotaxically 
instrumented with a chronic guide cannula (C315GS, Plastics One Inc., Roanoke, 
VA, USA) in the right lateral ventricle (AP: -0.5 mm, relative to Bregma; lateral: 1.25 
mm relative to the central suture; DV: -2.0 mm relative to the dura).  Patency of the 
cannula was assessed after recovery from surgery by central injection of 250 ng 
angiotensin II (H-1750, Bachem Americas, Inc., Torrance, CA, USA) in 0.5 µl 
pyrogen-free saline (PFS).  If the cannula is patent and ventricular circulation 
unobstructed, angiotensin II stimulates a drinking response upon activation of pre-
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optic structures (Epstein et al., 1970; Skott, 2003).  Only mice with positive drinking 
responses were included in experimental analyses. 
Analgesia for all surgical procedures was provided at the time of surgery by 
subcutaneous (SC) injection of buprenorphine (0.05 mg/kg) as well as topical 
application of 4% lidocaine at the incision site.  Penicillin (1,200,000 IU/kg; SC) and 
topical triple antibiotic treatment of the surgical site was also provided to minimize 
risk of infection.  Additional buprenorphine (0.03 mg/kg; SC) was administered 24 h 
post-surgery.  Animals were allowed at least seven days recovery prior to initiation of 
experimental protocols. 
 
Data Acquisition 
EEG and temperature data were obtained by connecting the mice to a 
lightweight flexible tether that allowed unrestricted movement as previously 
described (Baracchi and Opp, 2008).  Cage activity was monitored by an infrared 
sensor (BioBserve, GmbH, Bonn, Germany). Digitized EEG signals stored as binary 
files for subsequent analysis. 
Arousal state was determined by visual inspection of the EEG, theta-to-delta 
ratio, brain temperature, and cage activity with 10 s resolution using custom software 
(ICELUS, M. Opp, University of Washington) written in LabView for Windows 
(National Instruments, Austin, Texas, USA) based on previously published criteria 
(Opp and Krueger, 1994; Opp, 1998).  Epochs containing artifacts were excluded 
from subsequent spectral analyses.  The EEG underwent fast Fourier transformation 
(FFT) to produce power spectra between 0.5 and 30 Hz in 0.5 Hz bins as previously 
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described (Baracchi and Opp, 2008).  Spectral bins within the delta band (0.5 – 4.5 
Hz) were normalized to the total NREM power summed across all frequency bins 
from 0.5 to 30 Hz for the 12h dark and light periods and expressed as a percentage 
of total power.  Hourly NREM delta power data from the dark and light periods were 
normalized to 12 h dark and light averages, respectively, derived from control 
conditions. 
 
Central administration of IL-1 
After recovery from surgery and adaptation to the recording apparatus, WT (n 
= 4), NSE-IL1R1 (n = 5), and GFAP-IL1R1 (n = 5) mice were injected i.c.v. in a 
counterbalanced schedule with vehicle (PFS; 0.5 µl) and 50 ng recombinant mouse 
IL-1β (401-ML-005/CF, R&D Systems Minneapolis, MN, USA).  All injections were 
given 15 min prior to dark onset, and recordings obtained for 48 h. 
 
Cytokine quantification 
Two groups of mice were used to determine the effects of IL-1 administration 
on cytokine protein concentrations in brain.  The first group [WT (n = 6), NSE-IL1R1 
(n = 7), GFAP-IL1R1 (n = 6)] received a single i.c.v. injection of vehicle (PFS; 0.5 µl).  
The second group [WT (n = 6), NSE-IL1R1 (n = 7), GFAP-IL1R1 (n = 7)] was 
injected with 50 ng IL-1β in 0.5 µl PFS.  All injections were given at light onset in 
order to optimize protein detection.  Mice were lightly anesthetized and sacrificed via 
decapitation 4 h post-injection.  Brains were extracted, and the hypothalamus, 
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hippocampus, and brainstem dissected.  Samples were snap frozen in liquid 
nitrogen and stored at -80°C for subsequent protein extraction. 
Frozen tissues were thawed and lysed in a buffer containing cell lysis buffer 
from the Bio-Rad Cell Lysis Kit (171-304012, Bio-Rad, Hercules, CA, USA), 500 mM 
phenylmethanesulfonyl fluoride (P7626PMSF, Sigma-Aldrich, St. Louis, MO, USA), 
and 1% protease inhibitor (S8830, Sigma-Aldrich).  Tissue was mechanically 
disrupted using an ultrasonicator.  The resulting homogenate was centrifuged for 20 
min at 8,000 rpm at 4°C and the supernatant removed. 
The protein concentration of each sample was determined using the 
bicinchoninic acid (BCA) protein assay kit (23225, Thermo Scientific, Rockford, IL, 
USA).  Bovine serum albumin (BSA) was used to generate the standard curve.  
Sample absorbances were read at 562 nm on a spectrophotometer. 
IL-1 and IL-6 protein concentrations were quantified using a bead-based 
assay and Luminex xMAP technology (Luminex Corporation, Austin, TX, USA).  
Custom beads sets were developed in the lab using Luminex MagPlex microspheres 
(regions 34 and 38 for IL-1β and IL-6, respectively). Beads were conjugated to 
capture antibodies from IL-1β (DY401) and IL-6 DuoSets (DY406, R&D Systems) via 
the xMAP Antibody Coupling Kit (40-50016, Luminex Corporation). 
Diluents were generated as appropriate for the sample type: cell lysis buffer 
(171-304012, Bio-Rad) for protein extracts and 0.1% BSA in phosphate buffered 
saline (PBS) for cell culture supernatant.  IL-1 and IL-6 recombinant proteins were 
used to generate a 7-point standard curve (27, 81, 247, 741, 2,222, 6,667 and 
20,000 pg/mL).  Samples were loaded in duplicate, and IL-1 and IL-6 were detected 
57 
 
by sequential 30 min incubations with the respective DuoSet detection antibodies 
and streptavidin-phycoerythrin (S866, Life Technologies). 
The plate was read on the Bio-Plex 200 system (Bio-Rad) and data analyzed 
using Bio-Plex Manager 4.1 software with five-parameter logistic regression (5PL) 
curve fitting.  Observed concentrations were obtained from the Bio-Plex software for 
all sample types.  The cutoff for level of detection was set at the lowest point on the 
standard curve with an observed concentration between 70-130% of the 
(observed/expected)*100 value, as suggested by the Bio-Plex 200 manufacturers.  
Observed concentrations obtained from brain tissue were adjusted for sample 
protein concentrations determined from BCA assay, and final are values expressed 
as pg/mL/µg of protein loaded. 
 
Cell culture 
Whole brains from NSE-IL1R1 P0 – 2 pups were harvested to generate 
neuronal cultures.  Neurons were plated on poly-L-lysine coated coverslips at a 
density of 80,000 cells/cm2 in 24-well plates in NbActiv4 media (Nb4-500, BrainBits, 
LLC, Springfield, IL, USA) containing 1% penicillin-streptomycin-glutamine (10378-
016, Life Technologies).  Cultures were incubated at 37°C with 5% CO2 and 
received a 50% media change every 3 – 4 days.  Neuronal cultures were ready for 
experimental use 12 – 14 days post-plating. 
Astroglial cultures were obtained from whole brains of P0 – 2 GFAP-IL1R1 
pups and cultured according to a protocol adapted from Schildege et al. (2013).  
Astrocytes were plated at 10 – 15 x 106 cells on poly-L-lysine coated T75 flask in 
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high glucose Dulbecco's Modified Eagle Medium (DMEM; 11965-092, Life 
Technologies) containing 10% heat inactivated fetal bovine serum (10082-147, Life 
Technologies) and 1% penicillin-streptomycin-glutamine.  Once astrocytes were 
confluent, cultures were astrocyte enriched via agitation on an orbital shaker.  
Resulting astrocytes were re-plated in two poly-L-lysine coated T75 flasks.  
Approximately 14 days post-split when cells were confluent, cells were trypsinized 
and evenly distributed to poly-L-lysine-coated 24-well plates.  Cultures were 
incubated at 37°C with 5% CO2.  Cells were ready for experimental use 24 – 48 h 
post-plating once confluent. 
Mature neuronal and astroglial cultures were subjected to three conditions: 
untreated, vehicle (0.1% BSA in PFS), or IL-1 (neuronal: 50 ng/well; astroglial: 10 
ng/well).  After 24 h, cell culture supernatant was aliquoted and stored at -80°C until 
cytokine analysis.  IL-6 protein was quantified via bead-based assay using Luminex 
xMAP technology as described above. 
 
Statistical analysis 
Statistical analyses were performed using SPSS for Windows (IBM 
Corporation, Armonk, NY, USA).  Data are presented as means ± standard error of 
the mean (SEM) or means ± standard deviation (SDEV), as appropriate.  Within 
strain comparisons for percentage of time in REMS and NREMS, normalized NREM 
delta power, and brain temperature were performed via a general linear model for 
repeated measures using time (hours) as the repeated measure and manipulation 
(PFS vs. IL-1) as the between-subjects factor.  
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Between strain comparisons for cytokine protein quantification were 
performed using a mixed-effects analysis of variance (ANOVA) designating 
manipulation (PFS vs. IL-1) and strain (WT, NSE-IL1R1, or GFAP-IL1R1) as 
between-subjects factors.  Post-hoc comparisons by Tukey’s HSD test were used to 
determine differences among mouse strains where appropriate. 
One-way ANOVA was used to determine IL-1 effects in cell culture using 
treatment (untreated, vehicle, IL-1) as the independent variable.  If statistically 
significant treatment effects were revealed, post-hoc comparisons by Tukey’s HSD 
test were used to determine differences among culture manipulations.  
An alpha level of p < 0.05 was accepted as indicating significant departures 
from control conditions or strain differences for all tests. 
 
Results 
Effects of IL-1 on sleep and temperature 
Intracerebroventricular administration of IL-1 (50 ng) altered sleep and brain 
temperature of WT mice but not of NSE-IL1R1 or GFAP-IL1R1 animals (Figure 3.1).  
IL-1 transiently increased NREMS, suppressed REMS and NREM delta power, and 
induced long-lasting fever in WT mice.  Repeated measures analysis revealed a 
manipulation effect of IL-1 on REMS in WT animals, but no subsequent hourly 
differences were revealed. 
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IL-1-induced cytokine expression in brain   
To determine impact of IL-1 on brain cytokine expression, mice were injected 
with either PFS or 50 ng IL-1, sacrificed 4 h later, and discrete brain regions 
dissected.  Protein content for IL-1 and IL-6 was determined in hypothalamus, 
hippocampus, and brainstem (Figure 3.2).  IL-1 administration induced IL-1 in 
hypothalamus and brainstem and tended to increase IL-1 in hippocampus of WT 
mice.  IL-1 also significantly increased IL-1 in hippocampus of NSE-IL1R1 mice and 
in hippocampus and brainstem of GFAP-IL1R1 animals.  Central administration of 
IL-1 increased IL-6 in all brain regions assayed in WT mice, but not in either of the 
transgenic mouse strains.   
 
IL-1-induced cytokine expression in cell culture 
In vitro responses of neurons and astrocytes to treatment with IL-1 were 
obtained from cultures of NSE-IL1R1 and GFAP-IL1R1 brains (Figure 3.3).  IL-6 
production by NSE-IL1R1 neurons and GFAP-IL1R1 astrocytes increased after 24-h 
challenge with 50 or 10 ng/well IL-1, respectively. 
 
Discussion 
Several lines of evidence demonstrate a role for IL-1 in sleep regulation 
[reviewed by [reviewed by (Krueger et al., 2011; Imeri and Opp, 2009)].  However, 
the cellular substrates of IL-1 effects on sleep are not fully elucidated.  This study 
aimed to determine the contributions of neurons and astrocytes to IL-1-induced 
alterations of sleep-wake behavior and immunomodulation.  To this end, we used 
61 
 
two transgenic mouse lines that express IL1R1 only in the CNS, and selectively on 
neurons (NSE-IL1R1) or astrocytes (GFAP-IL1R1).  Central administration of IL-1 
does not alter sleep or temperature of transgenic mice.  This effect may be due to 
impaired in vivo production of IL-6. 
Responses of WT mice to central administration of IL-1 are typical of those 
previously observed in rodents, including suppressed REMS, increased NREMS, 
diminished NREM delta power, and a prolonged febrile response (Opp et al., 1991; 
Opp and Krueger, 1991; Olivadoti and Opp, 2008).  Unexpectedly, IL-1 has no effect 
on sleep or temperature of the transgenic mice used in this study.  These data 
indicate that IL1R1 expression specifically on neurons or astrocytes alones is not 
sufficient for mediating sleep or temperature responses to exogenous IL-1. 
To determine potential mechanisms underlying these results, cytokine protein 
was quantified in brain tissue.  IL-1 stimulates its own production (Dinarello, 1988; 
Dinarello et al., 1987), and the elimination half-life of exogenous IL-1 is 
approximately 40 - 60 min (Reimers et al., 1991; Loddick and Rothwell, 1996).  
Therefore, IL-1 detected at our 4 h post-injection collection timepoint is de novo IL-1 
generated from exogenous IL-1 administration.  Indeed, central injection of IL-1 
induces de novo IL-1 production in all strains of mice.  Importantly, elevated IL-1 is 
not detected in hypothalamic tissue from transgenic mice, which may explain, at 
least in part, lack of sleep and temperature responses in these strains. 
In WT mice, IL-1 administration also increases IL-6 in brain, which is 
consistent with the literature (Romero et al., 1996; Tsakiri et al., 2008).  Interestingly, 
IL-1 administration does not increase IL-6 protein concentrations in these transgenic 
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mice.  Sleep and temperature responses to intracerebroventricular administration of 
IL-1 are attenuated in IL-6 knockout mice (Olivadoti and Opp, 2008).  Collectively, 
previously published data and results reported in this chapter suggest that IL-1-
induced fever and, to some extent, sleep responses are driven by subsequent 
production of IL-6.   
Interestingly, NSE-IL1R1 neurons and GFAP-IL1R1 astrocytes produce IL-6 
in response to IL-1 challenge in culture.  IL-1 binding to IL1R1 on neurons and 
astrocytes induces IL-6 release via unique pathways (Tsakiri et al., 2008).  It is 
unlikely that both neuronal- and astroglial-specific mechanisms of IL-1-induced in 
vivo IL-6 production are disrupted.  Therefore, inhibition of in vivo IL-6 likely occurs 
upstream of these pathways.  A potential source of inhibition may occur at the 
cellular level.  Endothelial cells are significant cellular substrates of IL-1 effects 
(Konsman et al., 2004; Thornton et al., 2010).  Fevers in response to central IL-1 
administration are attenuated in mice with inducible inhibition of IL1R1 on endothelial 
cells, and endothelial-specific IL1R1 knockdown reduces IL-1-induced hypothalamic 
c-Fos expression (Ching et al., 2007).  Therefore, as with fever, expression of IL1R1 
on endothelial cells may be necessary for sleep responses to central administration 
of IL-1.  Although additional experiments are necessary, endothelial IL1R1 might 
initiate IL-1-induced immune responses, whereas neuronal and astroglial IL1R1 may 
potentiate these effects.  Alternatively, concurrent neuronal and astroglial expression 
of IL1R1 may be necessary for behavioral and in vivo immunomodulatory responses 
to IL-1.  These cells do not work in isolation in the brain.  Some neuronal functions 
are dependent on astrocytes and vice versa (Stevens, 2008; Ghosh et al., 2011).  
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Further experimentation is needed to determine the central mechanisms of IL-1 
activity. 
Overall, this study demonstrates that neuronal- or astroglial-specific 
expression of IL1R1 is not sufficient for IL-1-induced alterations of sleep and 
temperature. Future studies may aim to identify independent or collaborative 
contributions of neurons, astrocytes, or other cellular substrates of IL-1 effects in the 
brain.  Continued investigation of the molecular contributions of astrocytes and other 
neural cells is crucial to fully elucidating the mechanistic underpinnings of a variety 
of CNS-mediated processes and behaviors.  
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Figure 3.1:  Percentage of recording time spent in REMS and NREMS, normalized 
NREMS delta power, and brain temperature responses obtained after central 
injection with PFS (open symbols) or IL-1 (filled symbols) for WT, NSE-IL1R1, and 
GFAP-IL1R1 mice.  Values are means ± SEM.  Hourly data for EEG delta power 
were normalized to 12 h dark and light averages obtained from PFS data.  Statistical 
analyses were conducted on 6 h time blocks.  Asterisk (*) denotes statistical 
difference of p < 0.05 from undisturbed baseline conditions. Dashed line indicates a 
statistically significant manipulation effect but no post-hoc significance.  The filled 
and open bars on the X-axis indicate dark and light periods of the light-dark cycle, 
respectively. 
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Figure 3.2:  Quantification of IL-1 and IL-6 protein extracted from hypothalamus, 
hippocampus, and brainstem of WT, NSE-IL1R1, and GFAP-IL1R1 mice harvested 
4 h post-i.c.v. injection with PFS or 50 ng IL-1.  Values are means ± SDEV.  Asterisk 
(*) indicates statistical difference of p < 0.05 from PFS.  Pound sign (#) denotes 
statistical difference of p < 0.05 from WT IL-1 values.   
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Figure 3.3:  Quantification of IL-6 protein from cell culture supernatant of NSE-IL1R1 
neuronal and GFAP-IL1R1 astroglial cultures that were untreated, treated with 
vehicle, or challenged with IL-1 (50 ng/well: neurons; 10 ng/well: astrocytes) for 24 h. 
Values are means ± SDEV.  Asterisk (*) indicates statistical difference of p < 0.05 
from untreated conditions.  Pound sign (#) denotes statistical difference of p < 0.05 
from vehicle. 
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CHAPTER IV 
 
 
SLEEP AND IMMUNOMODULATORY RESPONSES TO SYSTEMIC 
LIPOPOLYSACCHARIDE IN MICE WITH SELECTIVE INTERLEUKIN-1  
RECEPTOR 1 EXPRESSION ON NEURONS OR ASTROCYTES 
 
 
Abstract 
Sleep-wake behavior is altered in response to immune challenges.  Although 
the mechanisms that govern sickness-induced sleep changes are not fully 
understood, interleukin-1β (IL-1) is a known mediator of these interactions.  To 
further clarify the underlying substrates of sleep and inflammatory responses to 
immune challenge, we used two transgenic mouse strains that express interleukin-1 
receptor 1 only in the central nervous system and selectively on neurons (NSE-
IL1R1) or astrocytes (GFAP-IL1R1).  Electroencephalographic and temperature 
recordings from transgenic and wild type (WT) mice revealed systemic challenge via 
intraperitoneal administration of lipopolysaccharide (LPS) suppressed rapid eye 
movement sleep (REMS), increased non-REMS (NREMS), diminished NREM delta 
power, and induced febrile responses in all mouse strains.  However, GFAP-IL1R1 
mice had greater REMS suppression compared to NSE-IL1R1 animals and elevated 
NREM delta power compared to WT and NSE-IL1R1 mice.  Quantification of 
cytokine protein showed that LPS induces IL-1 and IL-6 production in NSE-IL1R1 
and GFAP-IL1R1 brain tissue but at concentrations generally less than those of WT 
mice.  This effect was more evident in GFAP-IL1R1 brain tissue.  However, 
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peripheral expression of these cytokines in transgenic plasma did not differ from WT.  
Taken together, these data suggest neuronal IL1R1 activity may modulate central 
aspects of pathological sleep and immunomodulatory responses to systemic 
challenge with LPS. 
 
Introduction 
Sleep and immune function are mutually influential.  Sleep loss impairs 
immune function, and sleep-wake behavior is modified in response to immune 
challenges [reviewed by (Imeri and Opp, 2009)].  Nevertheless, the mechanistic 
underpinnings of these interactions are not well understood.  However, the pro-
inflammatory cytokine interleukin -1β (IL-1) is an immunomodulator extensively 
implicated in mediating sleep and immune interactions.  
Systemic immune challenges triggers acute host defense responses that 
upregulate IL-1 in the brain and elicit clinical signs of illness (Van Dam et al., 1992).  
Indeed, symptoms of sickness, such as sleep-wake alterations, anorexia, loss of 
body weight, social withdrawal, and fever are induced by central administration of IL-
1 (Opp, 2005; Dantzer and Kelley, 2007).  Brain regions associated with the 
regulation of sleep-wake behavior, feeding, social behavior, and thermoregulation 
are immunoreactive for IL-1 (Breder et al., 1988; Konsman and Dantzer, 2001; Datta 
and Opp, 2008).   IL-1 is also a recognized sleep regulatory substance.  This 
distinction was earned, in part, by the ability of IL-1 administration to suppress rapid 
eye movement sleep (REMS) and increases non-REMS (NREMS) by acting on 
defined sleep circuitry (Olivadoti and Opp, 2008; Fang et al., 1998).  Furthermore, 
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inflammatory-induced alterations in sleep are attenuated by inhibition of IL-1 activity 
(Baracchi and Opp, 2008; Fang et al., 1998).  IL-1 exerts its effects via IL-1 receptor 
1 (IL1R1) which is constitutively expressed in the brain and present on neurons and 
astrocytes (Smith et al., 2009; Farina et al., 2007). 
Although neurons produce cytokines (Breder et al., 1988; Bartfai and 
Schultzberg, 1993), the majority of immunomodulator production and release is 
managed by glial cells such as astrocytes (Baumann et al., 1993; Dong and 
Benveniste, 2001; Mason et al., 2001).  Astrocytes express receptors for 
immunomodulators, respond rapidly to inflammation, and produce sleep regulatory 
substances in response to immune challenges (Halassa et al., 2007; Pinteaux et al., 
2002; Sugama et al., 2011; Farina et al., 2007; Ingiosi et al., 2013).  Recent studies 
also report that astrocytes regulate sleep homeostasis and physiology (Halassa et 
al., 2009; Frank, 2013; Nadjar et al., 2013).  However, it is unknown to what extent 
neuronal-glial interactions influence complex behavior and physiology during 
immune challenges. 
The objective of this study was to determine cellular contributions to systemic 
immune challenge by targeting IL1R1 expression specifically to neurons or 
astrocytes.  In these experiments, two lines of transgenic mice that express IL1R1 
only in the central nervous system (CNS) and selectively on neurons or astrocytes 
were administered lipopolysaccharide (LPS) intraperitoneally to determine the extent 
to which neurons and astrocytes mediate immune challenges of peripheral origin.  
LPS is a component of the Gram-negative bacteria cell wall that induces 
inflammatory cascades which includes IL-1 production (Datta and Opp, 2008).  The 
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behavioral and molecular analyses presented here provide foundational insights into 
the cellular intricacies of central responses to systemic immune challenge. 
 
Methods 
Animals 
Transgenic and wild type (WT) mice used for these studies were engineered 
by our lab as previously described in Chapter II.  Briefly, transgenic mice were 
designed on a background lacking IL1R1.  IL1R1 was rescued by driving expression 
to neurons with the rat neuron specific enolase [NSE; (Forss-Petter et al., 1990)] 
promoter or to astrocytes via the human glial fibrillary acidic protein [gfa2; (Brenner 
et al., 1994)] promoter.  Therefore, mice express IL1R1 only in the CNS and 
selectively on neurons or astrocytes.   Mice expressing IL1R1 specifically on 
neurons are called NSE-IL1R1, whereas mice with astroglial localized expression of 
IL1R1 are referred to as GFAP-IL1R1.  Heterozygous Il1r1+/- non-transgenic 
littermates were mated to generate mice homozygous positive for endogenous Il1r1 
(Il1r1+/+).  These homozygous mice served as WT controls for NSE-IL1R1 and 
GFAP-IL1R1 mice.   
During the studies, adult male WT, NSE-IL1R1, and GFAP-IL1R1 mice (20 – 
30 g, 8 – 12 weeks at time of surgery) were obtained from our breeding colony and 
individually housed in standard cages on a 12:12 h light:dark cycle at 29 ± 1ºC, an 
ambient temperature that is within the murine thermoneutral zone (Gordon and 
White, 1985; Rudaya et al., 2005).  Food and water were available ad libitum.  All 
procedures involving the use of animals were approved by the University of 
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Washington Institutional Animal Care and Use Committee in accordance with the US 
Department of Agriculture Animal Welfare Act and the National Institutes of Health 
policy on Humane Care and the Use of Laboratory Animals. 
 
Surgical procedures 
Mice used for electroencephalographic (EEG) recordings were stereotaxically 
instrumented under isoflurane anesthesia with three stainless steel screws (MPX-
0080-02P-C, Small Parts Inc., Logansport, IN, USA) and a calibrated 10 kΩ 
thermistor (AB6E3-GC16KA103L, Thermometrics, Northridge, CA, USA) as 
previously described (Baracchi and Opp, 2008).  Analgesia was provided at the time 
of surgery by subcutaneous (SC) injection of buprenorphine (0.05 mg/kg) as well as 
topical application of 4% lidocaine at the incision site.  Penicillin (1,200,000 IU/kg; 
SC) and topical triple antibiotic treatment of the surgical site was also provided to 
minimize risk of infection.  Additional buprenorphine (0.03 mg/kg; SC) was 
administered 24 h post-surgery.  Animals were allowed at least seven days recovery 
prior to initiation of experimental protocols. 
 
Data acquisition 
EEG and temperature data were obtained using a lightweight tethered 
swinging arm system which allowed for unrestricted cage navigation as previously 
described (Baracchi and Opp, 2008).  Cage activity was monitored by an overhead 
infrared sensor (BioBserve, GmbH, Bonn, Germany). Digitized EEG signals were 
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filtered using Chebyschev filters with third order coefficients into delta (0.5 – 4.5 Hz) 
frequency bands and stored as binary files for subsequent analysis. 
Arousal state was determined by visual inspection of the EEG, theta-to-delta 
ratio, brain temperature, and cage activity with 10 s resolution using custom software 
(ICELUS, M. Opp, University of Washington) written in LabView for Windows 
(National Instruments) based on previously published criteria (Opp and Krueger, 
1994; Opp, 1998).  Epochs containing artifacts were excluded from subsequent 
spectral analyses.  The EEG underwent fast Fourier transformation (FFT) to produce 
power spectra between 0.5 and 30.0 Hz in 0.5 Hz bins as previously described 
(Baracchi and Opp, 2008).  Spectral bins within the delta band (0.5 – 4.5 Hz) were 
normalized to the total NREM power summed across all frequency bins from 0.5 to 
30.0 Hz for the 12h dark and light periods and expressed as a percentage of total 
power.  Hourly NREM delta power data from the dark and light periods were 
normalized to 12 h dark and light averages, respectively, derived from control 
conditions. 
 
Systemic administration of LPS 
After recovery from surgery and habituation to the recording apparatus, WT (n 
= 7), NSE-IL1R1 (n = 7), and GFAP-IL1R1 (n = 7) mice received an intraperitoneal 
(i.p.) injection of vehicle [0.2 mL, pyrogen-free saline (PFS)].  After 48 h, mice 
received 0.4 mg/kg LPS (Escherichia coli serotype 0111:B4, Sigma-Aldrich, St. 
Louis, MO, USA).  All injections occurred 15 min prior to dark onset (DO).  Although 
it would be ideal to counterbalance saline and LPS injections, LPS challenge 
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occurred subsequent to vehicle administration as it is unknown how long the effects 
of LPS persist.  EEG and temperature data were collected for 48 h following each 
injection beginning at DO.  Daily body weight, food consumption, and water intake 
data were obtained via scale measurements 15 min prior to DO. 
 
Cytokine quantification 
Two groups of WT and transgenic mice were used to determine the impact of 
LPS on cytokine expression.  The first group [WT (n = 6), NSE-IL1R1 (n = 5), GFAP-
IL1R1 (n = 5)] received a single i.p. injection of vehicle (PFS; 0.2 mL).  The second 
group [WT (n = 7), NSE-IL1R1 (n = 7), GFAP-IL1R1 (n = 7)] was injected with 0.4 
mg/kg LPS i.p.  In order to improve probability of detection, injections occurred at 
light onset when the diurnal concentration of the proteins of interest are more 
elevated (Cearley et al., 2003; Guan et al., 2005).  All mice were anesthetized 4 h 
post-injection.  Blood was obtained via orbital bleed for subsequent plasma retrieval. 
Mice were then decapitated, and the hypothalamus, hippocampus, and brainstem 
were harvested and snap frozen in liquid nitrogen.  Blood was centrifuged for 20 min 
at 3000 rpm at 4°C, and the resulting supernatant (plasma) was collected.  All 
samples were stored at -80°C until subsequent analysis.  
Protein extractions and quantification were performed as previously described 
in Chapter III.  Briefly, frozen brain samples were transferred to lysis buffer (171-
304012, Bio-Rad, Hercules, CA, USA) to thaw.  Samples were then mechanically 
disrupted using an ultrasonicator, homogenates centrifuged, and the resulting 
supernatant stored at -80°C until further processing. The protein concentration of 
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each sample was determined using the bicinchoninic acid (BCA) protein assay kit 
(23225, Thermo Scientific, Rockford, IL, USA).   
IL-1 and IL-6 protein concentrations were quantified using a bead-based 
assay and Luminex xMAP technology (Luminex Corporation, Austin, TX, USA) as 
previously described in Chapter III.  Custom beads sets were developed using IL-1β 
(DY401, R&D Systems, Minneapolis, MN, USA) and IL-6 (DY406, R&D Systems) 
DuoSets via the xMAP Antibody Coupling Kit (40-50016, Luminex Corporation).  
Tumor necrosis factor α was also quantified but was not detected in WT or 
transgenic brain tissue samples (data not shown).  
Diluents were generated as appropriate for the sample type: cell lysis buffer 
(171-304012, Bio-Rad) for protein extracts and 5% normal donkey serum (017-000-
121, Jackson ImmunoResearch, West Grove, PA, USA) in phosphate buffered 
saline for plasma samples.  Samples were quantified in duplicate via the Bio-Plex 
200 system (Bio-Rad) and data analyzed using Bio-Plex Manager 4.1 software.  
Observed concentrations obtained from plasma samples are reported as pg/mL.  
Brain tissue values were adjusted for sample protein concentrations determined 
from BCA assay, and final are values expressed as pg/mL/µg of protein loaded. 
 
Statistical analysis 
Statistical analyses were performed using SPSS for Windows (IBM 
Corporation, Armonk, NY, USA).  Data are presented as means ± standard error of 
the mean (SEM) of means ± standard deviation (SDEV).  Within strain comparisons 
for percent time in REMS and NREMS, normalized NREM delta power, sleep state 
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transitions, and brain temperature were performed via a general linear model for 
repeated measures using time (hours) as the repeated measure and manipulation 
(PFS vs. LPS) as the between-subjects factor.  LPS effects on 12 h dark and light 
period NREM delta power and brain temperature means for each strain were 
analyzed with independent-samples t-test using manipulation (PFS vs. LPS) as the 
grouping variable. 
Between strain comparisons for calculated difference scores for LPS effects 
and normalized NREM delta power were performed in 12 h time blocks using one-
way analysis of variance (ANOVA) with strain (WT, NSE-IL1R1, GFAP-IL1R1) as the 
independent variable.  If statistically significant strain effects were revealed, post-hoc 
comparisons by Tukey’s HSD test were used to determine differences among 
mouse strains.  
Within and between strain comparisons for body weight, food and water 
intake, and cytokine protein quantification were performed using a mixed-effects 
ANOVA designating manipulation (PFS vs. LPS) and strain (WT, NSE-IL1R1, or 
GFAP-IL1R1) as between-subjects factors.  Post-hoc comparisons by Tukey’s HSD 
test were used to determine differences among mouse strains where appropriate. 
An alpha level of p < 0.05 was accepted as indicating significant departures 
from control conditions or strain differences for all tests. 
 
Results 
Effects of LPS on sleep and temperature 
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To determine the contributions of neuronal- and astroglial-driven IL1R1 
modulation of systemic immune responses, transgenic and WT mice were injected 
intraperitoneally (i.p.) with 0.4 mg/kg LPS.  In response to LPS, all mice exhibited 
REMS suppression during the dark and light periods, increased NREMS during the 
dark period, and a greater number of sleep state transitions 18 h post-injection 
compared to injection with PFS (Figure 4.1).  Additionally, repeated measures 
analysis revealed LPS induced a febrile response in WT mice during the light period, 
whereas GFAP-IL1R1 animals had a hypothermic response during the dark period.  
NSE-IL1R1 mice did not exhibit a significant, hourly temperature response to LPS.  
However, analysis of mean brain temperature for the 12 h dark and light periods 
showed LPS induced hypothermic responses in the dark period for WT and GFAP-
IL1R1 mice and light period febrile responses in all strains (Figure 4.1).  The NSE-
IL1R1 hypothermic response in the dark period trended towards significance. 
The influence of neuronal and astroglial IL1R1 on LPS alterations of NREM 
EEG spectra were also evaluated as an additional measure of sleep quality 
(Borbély, 1982).  Examination of the hourly responses demonstrated that LPS 
challenge diminished normalized NREM delta power for 18 h post-injection in WT 
mice which was followed by a significant rebound of NREM delta power (Figure 4.1).  
NSE-IL1R1 mice saw a small reduction in normalized NREM delta power at hour 12 
post-LPS administration compared to PFS.  Although LPS appeared to suppress 
NREM delta power on an hourly basis in GFAP-IL1R1 mice, these departures did 
not reach statistical significance.  However, examination of the 12 h means during 
the dark and light period revealed NREM delta power of WT and NSE-IL1R1 mice 
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was reduced during the dark period, whereas GFAP-ILR1 delta power was 
enhanced during the light period (Figure 4.1). 
In order to determine the magnitude of LPS effects on sleep-wake behavior 
and temperature among the WT and transgenic mice, differences scores from PFS 
conditions were calculated (Figure 4.2).  LPS manipulated NREMS and brain 
temperature to the same extent in all mouse strains.  However, GFAP-IL1R1 mice 
exhibited greater suppression of REMS 24 h post-injection compared to NSE-IL1R1 
animals.  Additionally, the NREM delta power of GFAP-IL1R1 mice saw an overall 
enhancement during the light period compared to WT and NSE-IL1R1 mice.  Finally, 
the sleep of NSE-IL1R1 mice was more consolidated following LPS challenge 
compared to WT and GFAP-IL1R1 animals as evidenced by fewer sleep state 
transitions. 
 
Impact of LPS on symptoms of clinical illness 
LPS effects on body weight, food consumption, and water intake in WT and 
transgenic mice were analyzed as additional clinical measures of immune response 
(Figure 4.3).  All mouse strains exhibited a reduction in body weight and food and 
water intake after LPS challenge.  Calculated difference scores revealed these 
responses were of the same magnitude for all strains except for NSE-IL1R1 water 
consumption which was lesser than that of WT mice.  Additionally, GFAP-IL1R1 
mice drank less water under control conditions compared to WT and NSE-IL1R1 
animals. 
 
81 
 
LPS-induced alterations of cytokine expression 
To more fully understand neuronal and astroglial contributions to LPS-
induced immune responses, cytokine proteins were quantified in discrete brains 
regions of WT and transgenic mice after i.p. administration of PFS and LPS (Figure 
4.4).  IL-1 and IL-6 protein concentrations were elevated after LPS challenge in 
hypothalamus, hippocampus, and brainstem of all mouse strains.  The only 
exception was increased NSE-IL1R1 hypothalamic IL-1 protein did not achieve 
statistical significance.  Although IL-1 and IL-6 protein concentrations did not differ 
among mouse strains under control conditions, NSE-IL1R1 production of IL-6 was 
blunted in hippocampus and brainstem compared to WT following LPS challenge.  
Attenuation of LPS-induced cytokine production in GFAP-IL1R1 brain regions was 
even more pronounced with statistically significant departures from WT in all 
conditions except for hypothalamic IL-1. 
IL-1 and IL-6 protein concentrations were also quantified in plasma to assess 
the effects of LPS on peripheral immune responses of WT, NSE-IL1R1, and GFAP-
IL1R1 mice (Figure 4.5).  LPS administration increased plasma concentrations of IL-
1 and IL-6 in all mouse strains.  Furthermore, transgenic plasma cytokine 
concentrations did not differ statistically from WT conditions. 
 
Discussion 
The aim of this study was to determine the contributions of neurons and 
astrocytes to sleep-wake behavior and immunomodulation during systemic immune 
challenge.  We used two transgenic mouse lines that express IL1R1 only in the 
82 
 
CNS, and selectively on neurons (NSE-IL1R1) or astrocytes (GFAP-IL1R1) to 
dissect cellular modulation of LPS effects.  In response to LPS, GFAP-IL1R1 mice 
have greater REMS suppression compared to NSE-IL1R1 mice and elevated NREM 
delta power compared to WT and NSE-IL1R1 mice.  Additionally, NSE-IL1R1 mice 
exhibit more consolidated sleep during LPS challenge.  Finally, LPS induces 
elevations in brain and plasma cytokine protein in WT and transgenic mice.  
However, transgenic cytokine expression in brain in many instances is blunted 
compared to WT conditions. 
In accordance with previous studies (Morrow and Opp, 2005; Nadjar et al., 
2013), systemic LPS administration decreases REMS in all mouse strains.  This 
effect is more pronounced in GFAP-IL1R1 mice compared to NSE-IL1R1 animals.  
Although numerous studies detail the suppressive influence of LPS on REMS, the 
mechanisms that underlie this alteration in sleep behavior are not well understood.  
However, it is known that IL-1 administration suppresses REMS (Olivadoti and Opp, 
2008; Fang et al., 1998), and this response is mediated, in part, by the serotonergic 
system (Brambilla et al., 2007; Manfridi et al., 2003).  Serotonergic neurons in dorsal 
raphe nucleus of the brainstem activate REM-OFF neurons to inhibit the occurrence 
of REMS (McCarley, 2007).  In genetically intact animals, LPS and IL-1 induce 
serotonin reuptake via stimulation of the serotonin transporter (SERT).  
Quantification of brainstem cytokine protein reveals LPS-induced IL-1 expression is 
attenuated in GFAP-IL1R1 mice.  The lack of IL-1 expression in GFAP-IL1R1 mice 
may limit SERT activity resulting in a greater concentration of serotonin in the 
extracellular space, and thus, prolonged activation of REM-OFF neurons.  However, 
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further experimentation is needed.  Whatever the mechanism may be, it is 
interesting to note that IL-1 expression in NSE-IL1R1 brainstem following LPS does 
not differ from GFAP-IL1R1 mice, yet REMS suppression is more pronounced in 
GFAP-IL1R1 animals.  Therefore, the variance of LPS-induced REMS suppression 
between GFAP-IL1R1 and NSE-IL1R1 mice despite similar central expression of IL-
1 suggests differential effects of neuronal- and astroglial- derived IL-1 on REMS 
circuitry during LPS immune challenge. 
Although NREMS is elevated to the same extent in WT and transgenic mice 
following challenge with LPS, alterations to the NREM EEG spectra differ among 
strains.  LPS reduces the percentage of the total NREM spectra distributed to the 
delta frequency band during the dark period in WT and NSE-IL1R1, but the 
magnitude of this effect is similar among WT and transgenic mice.  In the light 
period, however, LPS induced an overall elevation of NREM delta power in GFAP-
IL1R1 mice, an effect that was greater than WT and NSE-IL1R1 responses.  NREM 
delta power is considered a measure of sleep quality and depth (Borbély, 1982).  
Therefore, despite increased time spent in NREMS, these data suggest NREMS is 
less restorative in WT and NSE-IL1R1 mice compared to GFAP-IL1R1 mice in 
response to LPS.  Furthermore, neuronal IL1R1 activity may be driving LPS-induce 
reductions in NREM delta power.  
The mechanisms that govern NREM spectral characteristics have yet to be 
fully identified.  However, a recent study demonstrated that astrocyte-derived 
adenosine mediates LPS-induced alterations of delta power, and LPS effects on 
delta power are ameliorated by inhibition of astroglial gliotransmission (Nadjar et al., 
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2013).  Data from this current study are not entirely consistent with these findings.  
In contrast to the experiments presented here, LPS administration occurred at light 
onset in the study by Nadjar and colleagues which elevates NREM delta power.  
Therefore, the discrepancy may be due to the diurnal timing of immune challenge 
(Morrow and Opp, 2005).  Alternatively, LPS-induced gliotransmission may not be 
dependent on activation of astroglial IL1R1. 
An additional measure of sleep quality and efficiency is sleep state 
consolidation [reviewed by (Imeri and Opp, 2009)].  LPS increases the number of 
sleep state transitions in all mice, a response generally indicative of poorer sleep.  
However, sleep fragmentation is less robust in NSE-IL1R1 mice.  This study and 
others demonstrate LPS upregulates IL-1 in brain (Datta and Opp, 2008; Zielinski et 
al., 2013), and intracerebroventricular administration of IL-1 fragments sleep 
(Olivadoti and Opp, 2008).  Collectively, these data suggest that IL1R1 activation on 
astrocytes may modulate sleep state maintenance and/or transitions during LPS 
immune challenge. 
LPS effects on temperature were small on an hourly scale, but these 
responses accumulate during the dark and light periods for an overall hypothermic 
and febrile response, respectively, in WT and transgenic mice.  Furthermore, LPS 
alters temperature to the same extent across all mouse strains.  Considering that 
inhibition of IL-1 and IL1R1 activity does not eliminate fever in response to LPS 
(Lundkvist et al., 1999; Alheim et al., 1997; Leon, 1996), the data indicate that LPS-
induced temperature responses are not dependent on neuronal- or astroglial-specific 
expression of IL-1.  
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Consistent with the literature, LPS induces weight loss and attenuates feeding 
and drinking behavior in all mouse strains.  The magnitude of LPS effects on body 
weight and food intake do not differ among WT and transgenic mice.  This result is 
not entirely surprising as LPS induces weight loss and anorexia even in IL1R1 
knockout mice, effects that may be mediated more so by the periphery (Bluthé et al., 
2000).  In terms of drinking behavior, the effect of LPS on NSE-IL1R1 adipsia is 
attenuated compared WT suggesting astroglial IL1R1 activity may play a role in 
water intake.  Indeed, immunoreactivity of glial fibrillary acidic protein, an astroglial 
marker, fluctuates in accordance with hydration status in the supraoptic nucleus of 
the hypothalamus (Hawrylak et al., 1998).  Although the LPS-induced reduction of 
water intake GFAP-IL1R1 mice does not differ from WT or NSE-IL1R1 animals, 
GFAP-IL1R1 mice drink less water under control conditions.  These data suggest 
that neurons mediate physiological drinking responses, whereas astrocytes 
modulate water intake under pathological conditions. 
In order to better understand the underlying immune responses mediating 
behavioral alterations to LPS, cytokine protein was quantified.  LPS upregulates IL-1 
and IL-6 expression in brain and plasma of all mouse strains.  This effect is in many 
cases is less robust in transgenic brain tissue compared to WT.  Although the IL-6 
system is intact, IL-1 mediates IL-6 expression post-LPS (Luheshi et al., 1996; Kuida 
et al., 1995).  Therefore, reduced IL-1 protein expression likely accounts for the 
accompanying attenuation of IL-6 expression.   
Unlike brain cytokine expression, there were no statistically significant 
differences among the strains regarding IL-1 and IL-6 plasma concentrations in 
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response to LPS.  LPS actions are initiated by activation of toll-like receptor 4 
resulting subsequent production of cytokines including tumor necrosis factor α 
(TNF), IL-1, and IL-6.  Despite attenuated brain IL-1 and IL-6 expression in 
transgenic mice, NSE-IL1R1 and GFAP-IL1R1 animals still manifest behavioral 
responses to LPS challenge.  Taken together, these data may indicate that 
peripheral cytokine expression is driving the behavioral alterations to LPS, and IL-1 
and IL-6 may not be crucial mediators of these responses.  However, this is not 
likely the case as blockade of central responses to peripheral challenge can diminish 
manifestation of symptoms of sickness induced by LPS (Imeri et al., 2006; Luheshi 
et al., 1996; Morrow and Opp, 2005).  Although peripheral challenge with a low dose 
of LPS alters sleep and central immunomodulation through stimulation of vagal 
afferents, the high dose of LPS used in this study may affect central responses via a 
different mechanism (Zielinski et al., 2013) such as increasing blood-brain barrier 
(BBB) permeability (Xaio et al., 2001; Minami et al., 1998).  In fact, LPS itself can 
cross the BBB when administered peripherally at high doses (Banks and Robinson, 
2010).  Therefore, LPS may be acting directly at TLR4 receptors in the brain to alter 
sleep and temperature of the WT and transgenic mice. 
Behavioral responses to LPS in transgenic mice may also be modulated by 
compensatory actions of other cytokines such as TNF.  IL1R1 knockout mice are 
responsive to LPS challenge (Leon, 1996; Bluthé et al., 2000), but LPS effects are 
inhibited by antagonism of TNF in these animals (Bluthé et al., 2000).  Interestingly, 
TNF inhibition in wild type mice does not attenuate LPS-induced symptoms of 
sickness, thus indicating compensation by TNF in the absence of IL1R1 (Bluthé et 
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al., 2000).  Although in the current study IL1R1 in not entirely absent and central 
TNF expression was not detected in any condition (data not shown), these factors 
do not discount the possibility of some degree of immunomodulatory compensation 
of the IL-1 system.   
Overall, these studies demonstrate the complexity of cellular mechanisms 
that underlie behavioral and immune responses to inflammatory challenge.  To our 
knowledge, these are the first studies to investigate the sufficiency of neuronal- and 
astroglial-specific contributions to peripheral immune challenge.  Continued study of 
non-neuronal cells will be invaluable to better understanding a variety of CNS-
mediated processes and behaviors as they relate to sickness and disease. 
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Figure 4.1: Percentage of recording time spent in REMS and NREMS, normalized 
NREM delta power, sleep state transitions, and brain temperature responses 
obtained after i.p. injection with PFS (open symbols) or LPS (filled symbols) for WT, 
NSE-IL1R1, and GFAP-IL1R1 mice.  Values are means ± SEM.  Hourly data for 
EEG delta power were normalized to 12 h PFS averages for the dark and light 
periods.  Statistical analyses were conducted on 6 and 12 h time blocks.  Graphical 
insets for NREM delta power (Δ power) and brain temperature (Tbr) depict 12 h 
mean comparisons between PFS (open bars) and LPS (filled bars) effects for the 
dark (D) and light (L) periods.  Asterisk (*) denotes statistical difference of p < 0.05 
from PFS. The filled and open bars on the X-axis indicate dark and light periods of 
the light-dark cycle, respectively. 
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Figure 4.2:  Effects of intraperitoneal injection with LPS shown as differences from 
PFS for percent recording time spent in REMS and NREMS, normalized EEG delta 
power during NREMS, number of sleep state transitions, and brain temperature 
plotted in 12 h time blocks for WT, NSE-IL1R1, and GFAP-IL1R1 mice.  Values are 
means ± SEM.  Asterisk (*) indicates a statistical difference of p < 0.05 from WT.  
Pound symbol (#) denotes a statistical difference of p < 0.05 from NSE-IL1R1.  Filled 
and open bars on the X-axis indicate dark and light portions of the light-dark cycle, 
respectively. 
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Figure 4.3:  Effects of intraperitoneal administration of PFS and LPS on body 
weight, food intake, and water intake for WT, NSE-IL1R1, and GFAP-IL1R1 over a 
24 h period.  Values are means ± SEM.  Graphical insets depict differences from 
PFS.  Asterisk (*) denotes a statistical difference of p < 0.05 from PFS.  Pound sign 
(#) indicates a statistical difference of p < 0.05 from NSE-IL1R1 under the same 
condition.  Carrot symbol (^) shows statistical difference of p < 0.05 from WT 
difference scores. 
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Figure 4.4:  Quantification of IL-1 and IL-6 protein extracted from hypothalamus, 
hippocampus, and brainstem of WT, NSE-IL1R1, and GFAP-IL1R1 mice harvested 
4 h post-intraperitoneal injection with PFS or LPS.  Values are means ± SEM.  
Asterisk (*) indicates a statistical difference of p < 0.05 from PFS.  Pound sign (#) 
denotes a statistical difference of p < 0.05 from WT LPS values.   
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Figure 4.5:  Quantification of IL-1 and IL-6 protein in plasma from WT, NSE-IL1R1, 
and GFAP-IL1R1 mice collected 4 h post-intraperitoneal injection with PFS or LPS.  
Values are means ± SDEV.  Asterisk (*) denotes a statistical difference of p < 0.05 
from PFS.  n.d. indicates where values were not detected. 
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CHAPTER V 
 
 
GENERAL DISCUSSION 
 
 
Introduction 
The findings presented in this dissertation suggest that neurons and 
astrocytes impart differential effects on sleep-wake behavior and immunomodulation 
as mediated by interleukin-1 receptor 1 (IL1R1).  These studies utilized novel strains 
of transgenic mice that were engineered to express IL1R1 only in the central 
nervous system (CNS) and selectively on neurons (NSE-IL1R1) or astrocytes 
(GFAP-IL1R1).  The transgenic mice described here allow for in vivo investigations 
of neuronal- and astroglial-driven modulation of physiology and behavior.  This final 
chapter will briefly summarize the findings and their implications within a broader 
context. 
 
Spontaneous sleep 
The experiments in Chapter II demonstrate that selective expression of IL1R1 
on neurons or astrocytes modulates physiological sleep.  Compared to wild type 
(WT) mice, transgenic mice spend a comparable amount of time in non-rapid eye 
movement sleep (NREMS) but exhibit more rapid eye movement sleep (REMS).  
Interestingly, IL1R1 deficient mice spend less time in NREMS but display normal 
amounts of REMS (Fang et al., 1998).  These data suggest neuronal and astroglial 
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IL1R1 modulate spontaneous sleep responses which is characterized, in part, by 
altered sleep architecture.   
Although our lab generally views NREM delta power as a measure of sleep 
quality and depth, others consider it an indicator of sleep pressure (Franken et al., 
2001).  Based on this latter distinction, baseline data indicate that transgenic mice, 
which exhibit elevated NREM delta power, are “sleepier” despite spending 
comparable amounts of time in NREMS and wakefulness relative to WT animals.  
The increased time spent in REMS, therefore, may reflect an intrinsic REM rebound 
in transgenic mice.  Nevertheless, these data suggest neuronal- and astroglial-
specific IL1R1 expression contributes to electroencephalographic (EEG) spectral 
characteristics under physiological conditions. 
 
Sleep deprivation 
Unlike IL1R1 knockout mice (Schmidt and Wisor, 2012), the percentage of 
time transgenic mice spend in REMS, NREMS, and wakefulness after sleep 
deprivation does not differ from WT.  These data (presented in Chapter II) suggest 
that neuronal or astroglial IL1R1 expression is sufficient for normal spontaneous 
sleep duration during the post-deprivation recovery period.  Consistent with previous 
findings demonstrating astrocytes mediate EEG slow-wave delta activity following 
sleep deprivation (Halassa et al., 2009), NSE-IL1R1 delta power response to 6 h of 
sleep deprivation is impaired compared to WT mice.  Therefore, astroglial IL1R1 
activity may modulate sleep homeostasis. 
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Response to central IL-1 
The most surprising result of this dissertation is the lack of response to 
interleukin-1β (IL-1) in transgenic mice (Chapter III).  Intracerebroventricular 
administration of IL-1 fails to alter sleep or temperature in NSE-IL1R1 and GFAP-
IL1R1 mice, indicating that expression of IL1R1 on neurons or astrocytes alone is 
not sufficient to manifest responses to central challenge with IL-1.  This effect may 
be mediated, in part, by the inability of NSE-IL1R1 and GFAP-IL1R1 mice to 
produce IL-6 in brain subsequent to IL-1 challenge.  Indeed, effects of central IL-1 
administration on NREMS and fever are attenuated in IL-6 deficient mice (Olivadoti 
and Opp, 2008).  However, NSE-IL1R1 neuronal and GFAP-IL1R1 astroglial cell 
cultures produce IL-6 in response to IL-1.  These data suggest additional 
mechanisms or substrates are required for in vivo IL-1 activity.  For example, 
simultaneous neuronal and astroglial expression of IL1R1 may be required to elicit 
responses to IL-1, or other cell types, such as endothelial cells, might initiate central 
responses to IL-1 (see below). 
 
Response to systemic LPS 
In Chapter IV, responses to lipopolysaccharide (LPS) are largely preserved in 
transgenic mice, as evidenced by decreased REMS, increased NREMS, elevated 
NREM delta power, and fever.  However, GFAP-IL1R1 mice exhibit greater REMS 
suppression compared to NSE-IL1R1 animals and have more NREM delta power 
than WT and NSE-IL1R1 mice.  These data suggest neuronal IL1R1 activity may 
drive aspects of pathological responses to LPS.  These data stand somewhat in 
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contrast to previous findings that astrocyte gliotransmission mediates slow-wave 
delta activity in response to LPS (Nadjar et al., 2013).  Our data do not discount the 
possibility that astrocytes modulate NREM delta power responses to LPS but merely 
suggest that LPS-induced gliotransmission may not be dependent on activation of 
astroglial IL1R1. 
Although transgenic mice exhibit behavioral responses to LPS, cytokine 
production is impaired.  LPS induces IL-1 and IL-6 production in NSE-IL1R1 and 
GFAP-IL1R1 brain tissue but at concentrations generally less than those observed in 
WT samples.  However, peripheral expression of these cytokines is unaffected in 
transgenic mice.  The differential immunomodulatory responses to LPS may be due 
to reduced IL1R1 expression at the blood-brain barrier in transgenic mice, whereas 
sustained behavioral responses to LPS may result from compensatory actions of 
other cytokines such as tumor necrosis factor α (TNF) (see below). 
 
Mediators of sleep and immune responses 
The data presented in this body of work exemplify the complexity of sleep and 
immune interactions.  Although these studies demonstrate neurons and astrocytes 
are active contributors to sleep and immunomodulation, the results also implicate the 
contributions of additional substrates that were beyond the scope of these 
experiments.  These putative downstream and upstream mediators of neuronal and 
astroglial modulation of sleep and immune interactions may exist at both molecular 
and cellular levels. 
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Adenosine 
Adenosine is a sleep regulatory substance that serves to promote sleep, in 
part, by inhibiting wake-promoting neurons (Alam et al., 1999; Basheer et al., 2004).  
For example, adenosine inhibits cholinergic and non-cholinergic neurons of the 
wake-promoting basal forebrain (Basheer et al., 2004), an effect linked to increased 
delta power and suppressed theta activity (Cape and Jones, 2000).  Furthermore, 
microinjections of an adenosine agonist into the brainstem increases REMS (Marks 
and Birabil, 1998), and systemic administration of adenosinergic agonists increases 
time spent in NREMS and REMS (Radulovacki et al., 1984).  Recently, Halassa et 
al. (2009) reported that impaired astrocytic gliotransmission reduces compensatory 
EEG delta power responses to sleep deprivation and that this effect is mediated by 
adenosine.  In Chapter II, NSE-IL1R1 mice were found to have less NREM delta 
power following 6 h of sleep deprivation.  This finding raises the possibility that 
astroglial-specific IL1R1 signaling facilitates gliotransmission of adenosine.  Indeed, 
IL-1 induces adenosine production (Sperlagh et al., 2004; Zhu et al., 2006).  
Likewise, adenosine triggers signaling via nuclear factor-κB (NF-κB) (Basheer et al., 
2001), a transcription factor that induces IL-1 expression.  Furthermore, LPS-
induced elevations of EEG slow wave activity are attenuated in gliotransmission-
impaired mice (Nadjar et al., 2013).  This effect is mimicked by central inhibition of 
the adenosine 1 receptor (Nadjar et al., 2013).  Taken together, adenosine may be a 
downstream mediator of neuronal- and astroglial-driven IL1R1 modulation of sleep 
and immune responses.  These findings demonstrate a need for further investigation 
of adenosine in sleep-immune interactions. 
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Interleukin-6 
IL-6 is pro-inflammatory cytokine that is an important downstream mediator of 
IL-1 activity (Tsakiri et al., 2008).  IL-6 deficiency attenuates IL-1- and LPS-induced 
alterations in NREMS and febrile responses (Olivadoti and Opp, 2008; Morrow and 
Opp, 2005a).  As with transgenic animals, IL-6 knockout mice spend more time in 
REMS but do not differ from WT with respect to spontaneous NREMS duration 
(Morrow and Opp, 2005b).    In Chapters III and IV, IL-6 production was impaired in 
transgenic brain tissue in response to immune challenge.  Although IL-6 protein was 
not quantified under baseline conditions, IL-6 production may be impaired in 
transgenic mice, thus contributing to the spontaneous sleep phenotypes described in 
Chapter II.  Interestingly, cultured NSE-IL1R1 neurons and GFAP-IL1R1 astrocytes 
produce IL-6 in response to IL-1.  These data indicate that, in transgenic mice, some 
in vivo inhibitory factor is in place.  A potential candidate for this IL-6 inhibition is the 
endothelial cell. 
 
Endothelial cells 
Endothelial cells are the primary cellular constituent of the blood-brain barrier 
(BBB).  These cells express IL-1 receptors (Konsman et al., 2004) and are activated 
by IL-1 (Thornton et al., 2010).   Endothelial-specific knockdown of IL1R1 abolishes 
IL-1-induced fever (Ching et al., 2007).  Furthermore, inducible inhibition of 
endothelial IL1R1 inhibits elevation of IL-1 concentrations and anxiety responses 
due to repeated social defeat (Wohleb et al., 2014).  Although endothelial cells are 
widely implicated in immune responses, we are not aware of any studies that 
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investigate endothelial-specific modulation of sleep-wake behavior.  On the other 
hand, studies report that sleep affects endothelial cells.  Chronic sleep restriction 
impairs BBB function and increases its permeability (He et al., 2014).  REMS 
restriction also increases BBB permeability, and BBB integrity can be restored by 
sleep recovery (Gómez-González et al., 2013).  Taken together, expression of IL1R1 
on endothelial cells may be necessary to initiate sleep responses to central 
administration of IL-1 and could be a source of IL-1-induced IL-6 production.  In light 
of the findings presented in Chapter III, futures studies should explore endothelial-
specific contributions to sleep-immune interactions. 
 
Neuronal-astroglial interactions 
Although this dissertation investigates the extent to which IL1R1 signaling in 
neurons or astrocytes is sufficient for the regulation of sleep-wake behavior and 
immunomodulation, these cells do not work in isolation.  In vitro studies show that 
some neuronal functions are dependent on astrocytes and vice versa.  Astrocytes 
mediate synaptic development and plasticity (Stevens, 2008), confer neuroprotection 
against immune effector cells (Darlington et al., 2008), and regulate hippocampal 
neurogenesis (Song et al., 2002).  Likewise, neurons influence astroglial expression 
of glutamate transporters (Swanson et al., 1997) via activation of NF-κB (Ghosh et 
al., 2011).  Neurons also mediate astroglial proliferation (Hatten, 1987).  Some of 
these interactions are modulated by secreted factors (Seil et al., 1992; Hayashi et 
al., 1988), whereas others manifest from direct cellular contact (Hatten, 1987).  To 
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address this concern, NSE-IL1R1 and GFAP-IL1R1 mice could be bred to produce 
progeny that express IL1R1 on both neurons and astrocytes. 
 
Methodological considerations 
To our knowledge, these are the first in vivo studies to investigate the 
sufficiency of neuronal and astroglial contributions to sleep and immune interactions.  
As such, data derived from the novel transgenic mouse strains introduced here are 
met with some unknowns.  Due to the nature of the transgenic mechanism, IL1R1 
may be overexpressed on neurons and astrocytes of transgenic mice.  Although 
IL1R1 expression in brain is constitutive and widespread (Breder et al., 1988; Farrar 
et al., 1987; Takao et al., 1990; Yabuuchi et al., 1994), it is currently unclear whether 
IL1R1 distribution differs from wild type conditions.  Additionally, the IL-1 system is 
self-mediated by a number of negative regulatory factors including the decoy 
receptor IL1R type II (McMahan et al., 1991), the endogenous IL-1 receptor 
antagonist (Hannum et al., 1990), and the IL-1 receptor brain-specific accessory 
protein (Taishi et al., 2012).  The impact of transgenic IL1R1 expression on these 
system components is currently unknown.   
IL-1 also produces a number of secondary mediators that exhibit inhibitory 
autocrine and paracrine effects on IL-1 activity.  These factors include anti-
inflammatory cytokines such as IL-4 and IL-10 (Pousset et al., 1999; Fiorentino et 
al., 1991).  Although IL-4 and IL-10 were not detected at our experimental timepoint, 
this does not discount the potential influence of these and other anti-inflammatory 
cytokines on IL-1 activity in NSE- and GFAP-IL1R1 mice.  Additionally, IL-1 activates 
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the hypothalamic-pituitary-adrenal (HPA) axis including corticotropin-releasing 
hormone expression (Opp and Imeri, 2001) and glucocorticoid release (Knudsen et 
al., 1987; Lee et al., 1988) that subsequently inhibits IL-1.  The impact of IL-1 on the 
HPA axis and its mediators in these transgenic mice has not been investigated.  
Lastly, due to the redundancy of the cytokine cascade of which IL-1 is a component, 
TNF is known to impart compensatory actions in IL1R1 deficient mice during 
challenge with LPS (Bluthé et al., 2000).  Although IL1R1 expression is rescued in 
neurons and astrocytes in transgenic mice, it is unclear if this pattern of receptor 
expression triggers compensatory responses of other cytokines. 
 
Non-neuronal contributions 
A primary objective at the onset of this project was to contribute information 
regarding the role of non-neuronal cells, particularly glia, in physiology and behavior.  
Glia were traditionally relegated to supportive, passive constituents of the CNS.  
However, recent studies are emphasizing the active contributions of these cells to 
physiology, behavior, and disease.  As such, these investigations reveal the extent 
of our lack of understanding regarding CNS-mediated processes and the associated 
mechanistic underpinnings.  Although the studies presented in previous chapters 
explore the role of astrocytes in sleep and immune function, these cells and others 
are implicated in variety of CNS-mediated process.  For example, astrocytes actively 
contribute to synaptic plasticity (Araque et al., 1999; Stevens, 2008) as well as 
learning, memory, and cognition (Gerlai et al., 1995; Halassa et al., 2009; Han et al., 
2013).  Furthermore, astroglial impairments are implicated in disorders of 
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metabolism [reviewed by (Yi et al., 2011)], aging [reviewed by (Ingiosi et al., 2013)], 
and depression [reviewed by (Smialowska et al., 2013)], as well as 
neurodegenerative disorders such as Alzheimer's disease [reviewed by (Avila-
Muñoz and Arias, 2014)] and Parkinson's disease [reviewed by (Niranjan, 2014)].  
Additional glial cells such as microglia also actively contribute to these and other 
CNS processes and disorders. 
Microglia are touted as resident immune cells of the CNS that are mobilized 
and activated in response to an immune challenge.  The role of microglia in 
mediating responses to immune challenge has been studied exhaustively.  However, 
microglia are now implicated as active contributors to physiological processes and 
behavior as well.  Intraperitoneal administration of minocycline, an inhibitor of 
microglial activation, induces an acute increase in wakefulness and significantly 
reduces NREMS compared to saline-treated mice (Wisor et al., 2011).  Minocycline 
also reduces EEG slow wave delta activity (Kim and Suh, 2009).  In response to 
sleep deprivation, microglia assume a deramified morphology, a marker of activation 
(Hsu et al., 2003).  In addition to their role in sleep, microglia also contribute to other 
physiological processes such as aging [reviewed by (Ingiosi et al., 2013)], as well as 
synaptic plasticity, learning, and memory [reviewed by (Morris et al., 2013; Schafer 
et al., 2013)].  These findings offer just a sampling of topics that merit further 
investigation of non-neuronal contributions to CNS-mediated processes and 
behaviors. 
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Concluding remarks 
The studies that comprise this dissertation demonstrate, through the use of 
novel transgenic mice, that neurons and astrocytes differentially mediate aspects of 
sleep and immunomodulation under physiological and pathological conditions.  To 
our knowledge, these experiments are the first to explore the sufficiency of neuronal 
and astroglial contributions to sleep and immune interactions in vivo.  Investigations 
into the role of astrocytes in sleep-wake behavior are in their infancy, and these 
studies contribute to a limited, but growing, body of work exploring active glial 
contributions to complex physiology and behavior.  Overall, these studies illustrate 
the complexity of cellular mechanisms that underlie behavioral and immune 
interactions.  Continued study of non-neuronal cells will be crucial to better 
understanding a variety of CNS-mediated processes and behaviors as they relate to 
physiology, sickness, and disease. 
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APPENDIX A 
 
 
SLEEP AND IMMUNE FUNCTION:  
GLIAL CONTRIBUTIONS AND CONSEQUENCES OF AGING 
 
 
Presented here is a published review that discusses recent findings that 
demonstrate a role for glia, specifically astrocytes and microglia, in sleep and 
immune interactions with an emphasis on cytokines.  The conversion continues in 
regards to how sleep, immune function, and cellular phenotypes change as a 
function of aging. 
 
Abstract 
The reciprocal interactions between sleep and immune function are well-
studied.  Insufficient sleep induces innate immune responses as evidenced by 
increased expression of pro-inflammatory mediators in the brain and periphery.  
Conversely, immune challenges upregulate immunomodulator expression, which 
alters central nervous system-mediated processes and behaviors, including sleep.  
Recent studies indicate that glial cells, namely microglia and astrocytes, are active 
contributors to sleep and immune system interactions.  Evidence suggests glial 
regulation of these interactions is mediated, in part, by adenosine and adenosine 5’-
                                                          
 This review was previously published: Ingiosi AM, Opp MR, Krueger JM (2013) Sleep and immune 
function: glial contributions and consequences of aging. Curr Opin Neurobiol 23:806-811. 
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triphosphate actions at purinergic type 1 and type 2 receptors.  Furthermore, 
microglia and astrocytes may modulate declines in sleep-wake behavior and 
immunity observed in aging.  
 
Introduction 
Chronic insufficient sleep is associated with inflammation, metabolic 
syndrome, cardiovascular disease, increased sensitivity and to pain stimuli, fatigue, 
excessive daytime sleepiness, and impaired cognitive and physical performance.  
Symptoms of these pathologies are associated with increased levels of endogenous 
pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor 
α (TNFα), and can be experimentally elicited by peripheral or central exogenous 
administration of these cytokines to subjects (Dantzer, 2001, Imeri and Opp, 2009).    
Conversely, inhibition of IL-1β or TNFα attenuates many sleep-loss associated 
symptoms. Additionally, reduction of endogenous levels of IL-1β or TNFα, whether in 
mutant mice or by use of soluble receptors, antibodies, or receptor antagonists, 
inhibits spontaneous sleep (reviewed (Imeri and Opp, 2009), (Krueger et al., 2008), 
and (Krueger, 2011)).  There is a wealth of evidence indicating that IL-1β and TNFα 
are also involved in physiological sleep regulation and that their amplification during 
pathology is causative of characteristic sleep disturbances associated with many 
pathological states (Krueger et al., 2008, Imeri and Opp, 2009, Krueger, 2011).  
Indeed, the brain, including regions associated with the regulation of sleep-wake 
behavior, produces and is responsive to cytokines (Krueger et al., 2008, Dantzer, 
2009, Imeri and Opp, 2009).  Furthermore, neuronal activity upregulates these 
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cytokines in brain regions implicated in the regulation of sleep (Churchill et al., 2008, 
Hallett et al., 2010).    Impaired sleep also affects adaptive immune responses.  
Sleep deprivation attenuates antibody responses to vaccine (Spiegel et al., 2002, 
Lange et al., 2003), whereas good sleep imparts long-lasting immunoenhancing 
effects (Lange et al., 2011•, Besedovsky et al., 2012).   Furthermore, sleep is a 
profound regulator of cellular immunity and formation of immunological memory 
critical for adaptive responses to immune challenges (reviewed by (Besedovsky et 
al., 2012)).  
We acquired substantial insight into sleep and immune system interactions 
during the last 30 years. However, the cellular substrates for these interactions are 
less well understood.  Understanding the role of glia in sleep and immune system 
functioning is crucial because research has started to shift the traditional view of 
these cells as passive constituents of the central nervous system (CNS) to active 
contributors capable of mediating behavior (see below).  Furthermore, because the 
aforementioned inflammatory pathologies are common in elderly individuals, 
identifying age-related changes in glial cell functioning may be critical in elucidating 
the mechanisms driving senescence of sleep and immune networks in aging.  This 
review highlights recent findings implicating a role for glia in sleep and immune 
interactions and aging. 
 
Microglia in sleep and immune function 
Microglia are the resident immune cells of the CNS that are mobilized and 
activated in response to an immune challenge.  The role of microglia in mediating 
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responses to immune challenge has been studied exhaustively.  Microglial 
influences on sleep-wake behavior are not extensively studied although recent data 
implicate microglia in sleep regulation.  Microglia assume a deramified morphology, 
a marker of activation, in response to sleep deprivation (Hsu et al., 2003).  In 
addition, slow wave activity is reduced following administration of minocycline, an 
inhibitor of microglial activation (Kim and Suh, 2009).  Minocycline inhibits microglial 
production of immunomodulators including cytokines and nitric oxide (Kim and Suh, 
2009).  Intraperitoneal minocycline administration induces an acute increase in 
wakefulness and significantly reduces non-rapid eye movement sleep (NREMS) 
compared to saline-treated mice (Wisor et al., 2011••).  Furthermore, minocycline 
inhibits sleep deprivation-induced augmentation of NREMS delta power, a surrogate 
indicator of sleep depth (Wisor et al., 2011••).  Although data are limited, recent 
studies indicate microglia are potentially critical components of sleep regulatory 
mechanisms. 
A possible effector of microglial influences on sleep-wake behavior may be 
extracellular adenosine-5’-triphosphate (ATP) acting at the purinergic type 2 receptor 
P2X7 (P2X7R).  The P2X7R links increased cellular activity during waking to 
adenosine and cytokine sleep modulation.  Activation of glial P2X7R by extracellular 
ATP mediates post-translational processing of sleep regulatory substances including 
IL-1β, TNFα, and IL-6 (Choi et al., 2007, Krueger et al., 2008, Mingam et al., 2008).  
P2X7R expression in brain is most prominent on microglia (Choi et al., 2007, Mingam 
et al., 2008), and neurons and glia release ATP into the extracellular space in 
response to cellular activity (Krueger et al., 2008).  Administration of P2X7R agonists 
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increases time spent in NREMS and enhances electroencephalographic (EEG) delta 
power (Krueger et al., 2010). Conversely, P2X7R inhibition reduces NREMS in rats 
(Krueger et al., 2010).  Furthermore, mice lacking the P2X7R exhibit less robust 
increases in NREMS and EEG delta power in response to sleep deprivation 
compared to wild type animals (Krueger et al., 2010).  Collectively, the data suggest 
a role for microglia and purinergic receptors as one component of systems and 
networks that mediate sleep and immune interactions (Figure A.1). 
 
Astrocytes in sleep and immune function 
A traditional view of astrocytes was that they played a passive, supportive 
role for neurons.  However, recent studies demonstrate that these cells are active 
contributors to complex behaviors and immune responses.  Astrocytes are the most 
abundant glial cell type in the brain, respond rapidly to inflammation, express 
receptors for immunomodulators, and produce sleep regulatory substances in 
response to immune challenge (Dong and Benveniste, 2001, Farina et al., 2007).  
Selectively inhibiting astrocyte gliotransmission via the dominant negative 
(dnSNARE) mouse reduces EEG slow wave activity during NREMS, a traditional 
measure of sleep pressure (Halassa et al., 2009)1.  Inhibition of vesicular release 
from astrocytes also attenuates the increase of NREMS and cognitive deficits 
typically observed subsequent to 6 h of sleep deprivation (Halassa et al., 2009).  
                                                          
1 EEG slow wave activity is regulated independently from duration of NREMS [Davis CJ, Clinton JM, 
Jewett KA, Zielinski MR, Krueger JM (2011) Delta wave power: an independent sleep phenotype or 
epiphenomenon? Journal of clinical sleep medicine : JCSM : official publication of the American 
Academy of Sleep Medicine 7:S16-18.  There is good evidence for the involvement of extracellular 
adenosine in its regulation; this might occur via vasodilation induced by adenosine since cerebral 
blood flow alters EEG slow wave power. 
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These data suggest astrocytic gliotransmission contributes to the modulation of 
sleep need.  
Because altered gliotransmission of astrocytes results in reduced sleep 
pressure, studies have turned to astrocyte-derived adenosine, an ATP metabolite, 
as a potential molecular substrate of this effect.  Adenosine accumulates in brain 
with increasing time awake (Schmitt et al., 2012••), and extracellular elevation of 
adenosine concentrations is astrocyte dependent (Pascual et al., 2005, Schmitt et 
al., 2012••).  Indeed, inhibition of the adenosine 1 receptor (A1R) in wild type mice 
recapitulates the reductions of baseline EEG slow wave activity and responses to 
sleep deprivation observed in gliotransmission-impaired dnSNARE mice (Halassa et 
al., 2009, Florian et al., 2011).  Conditional CNS A1R knockout mice also fail to 
demonstrate enhanced EEG delta power following intermittent sleep deprivation 
(Bjorness et al., 2009).  Conversely, mice lacking CD73, an ectonucleotidase that 
converts extracellular ATP to adenosine, have more spontaneous NREMS than wild 
type controls (Zielinski et al., 2012•).  Consistent with the notion that the A1R 
mediates sleep need, chronic sleep restriction increases A1R mRNA expression in 
the wake-promoting basal forebrain in rats (Kim et al., 2012) although not in the 
sleep-promoting hypothalamus of mice (Zielinski et al., 2012•).   
In response to immune challenge, A1R activity is upregulated to impart 
neuroprotection via generating neurotrophic factors, downregulating excitotoxicity, 
preventing excessive astrogliosis, and inhibiting pro-inflammatory cytokines (Barrie 
and Nicholls, 1993, Ciccarelli et al., 2001, Jhaveri et al., 2006, Lauro et al., 2010).  
Blockade of this receptor increases hippocampal injury in response to hypoxia 
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(Boissard et al., 1992) and mortality to infectious disease (Gallos et al., 2005).  
Furthermore, lipopolysaccharide (LPS)-induced elevations of EEG slow wave activity 
are attenuated in gliotransmission-impaired dnSNARE mice, an effect mimicked by 
central inhibition of the A1R in wild type mice (Nadjar et al., 2013••).  Although, 
studies regarding the impact of inhibiting the A1R or gliotransmission on sleep-
immune interactions are generally lacking, current data suggest astroglial 
modulation of sleep and immune function is mediated, in part, by astrocyte-derived 
ATP and/or adenosine and subsequent activation of purine type 1 and 2 receptors 
(Figure A.1).   
 
Sleep, immune function, and aging 
Sleep alterations are a well-documented feature of aging.  Sleep in old age is 
characterized by more fragmentation, less rapid eye movement sleep (REMS), 
reduced time in deeper stages of NREMS (i.e. stages N2 and N3), decreased EEG 
delta power, and more time spent in lighter stages of NREMS which results in more 
nighttime awakenings.  Furthermore, sleep onset is progressively earlier and is 
accompanied by early morning wake time and more frequent daytime napping (for 
review see (Singletary and Naidoo, 2011) and (Rolls, 2012)).  Although healthy 
aging need not be associated with sleep complaints,  the elderly frequently indicate 
they have difficulty initiating or maintaining sleep (Espiritu, 2008).  Increased severity 
of these alterations in sleep can increase susceptibility to disease and predict age-
related disease onset (Gibson et al., 2009, Postuma and Montplaisir, 2009).  Indeed, 
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several brain regions associated with sleep-wake behavior are impacted by 
neurodegenerative disease (Singletary and Naidoo, 2011). 
Poor sleep can also exacerbate the age-related changes in immune system 
functioning. “Inflammaging” is the term used to describe the homeostatic shift to a 
chronic, low-grade inflammatory state in aged individuals (Franceschi et al., 2007).  
This change is manifest by increased inflammatory mediators centrally and 
peripherally (Ye and Johnson, 1999), enhanced production of reactive oxygen and 
nitrogen species (Vishwas et al., 2012), as well as suppression of anti-inflammatory 
mediators and antioxidants (Ye and Johnson, 2001).  A similar syndrome is elicited 
by chronic sleep loss in younger subjects.  This shift predisposes one to 
exacerbated responses to immune challenge compared to that of normal, younger 
individuals.  Indeed, the severity of this low-grade inflammatory state is predictive of 
all-cause mortality in the elderly (Bauer, 2008).  Alternatively, longevity is inversely 
correlated with plasma concentrations of IL-6 (Maggio et al., 2006), a mediator of 
chronic inflammation in aging (Freund et al., 2010).  Inflammation is also implicated 
in contributing to poor sleep observed in the elderly.  However, recent data 
demonstrate that moderate exercise decreases pro-inflammatory cytokines IL-1β 
and TNFα and increases the anti-inflammatory cytokine IL-10 in aged individuals 
(Santos et al., 2012•, Speisman et al., 2012•).  This effect is associated with 
improved sleep maintenance and enhanced quality of life (Santos et al., 2012•).  
Exercise also increases circulating concentrations of neurotrophic factors which are 
associated with increased temporal lobe connectivity indicative of improved 
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neurocognition (Voss et al., 2013).  Lastly, better sleep efficiency is associated with 
lower concentrations of IL-6 in elderly women (Friedman et al., 2005). 
Although poor sleep in aged individuals increases immunomodulators and, 
likewise, inflammation alters sleep, the dynamics differ from those observed in 
younger counterparts.  For example, pre-clinical data demonstrate that 
intracerebroventricular administration of IL-1β reduces REMS to a similar extent in 
aged and middle-aged rats.  However, in aged rats, there is no observed increase in 
NREMS characteristic of IL-1β challenge in younger animals (Imeri et al., 2004).  
These data indicate a potential dysregulation of interactions between sleep and 
immune networks in aging.  Furthermore, the lack of NREMS response may 
contribute to increased morbidity and mortality in response to immune challenge in 
the elderly (Yoshikawa, 2000).  Studies regarding the cumulative effects of aging on 
sleep and immune function are generally lacking.  However, understanding these 
interactions is increasingly important with the rapid growth of the 65 years and older 
population.   
 
Glial contributions to aging 
Age-related changes of the CNS are not attributed to neuronal loss per se, 
but are a consequence of synaptic alterations, which may be due to decreased 
synaptic contacts (reduced dendritic spines) or molecular alterations of intact 
synapses (Hof and Morrison, 2004).  With age, there is a progressive decline in 
gene expression relating to vesicular function, receptor trafficking, post-synaptic 
density scaffolding, and neurotrophic systems (Berchtold et al., 2012).  Glia are 
124 
 
strong candidates for effectors of age-related alterations in sleep and immune 
function as these cells are known mediators of synaptic homeostasis (Wake et al., 
2009).  One of the characteristics of aging is a morphological shift of microglia and 
astrocytes to a primed or activated state (Franceschi et al., 2007, Dilger and 
Johnson, 2008).  Excessive and prolonged production of pro-inflammatory cytokines 
in aged CNS in response to systemic immune challenge with LPS is a result of 
primed microglia (Godbout et al., 2005, Henry et al., 2009).  Also, P2X7R expression 
increases with age in mouse brain, an effect associated with damage to the post-
synaptic density (Lee et al., 2011••).  Furthermore, astrocytes become 
hypersensitive after exposure to microglial-conditioned media, which may perpetuate 
the chronic inflammatory state in aging (Henn et al., 2011•).  Aging brain is 
associated with increased astrogliosis (Godbout et al., 2005), and astrocytes 
produce 10-fold more IL-6 in aged patients relative to younger counterparts (Bhat et 
al., 2012•).  Interestingly, peripheral concentrations of cytokines do not necessarily 
reflect neuroinflammatory states (Godbout et al., 2005).  Collectively, these data 
suggest that aging may be a centrally mediated process driven by glial alterations of 
the CNS milieu. 
 
Conclusions 
Reciprocal influences between sleep and immune system are well-
documented, but the cellular and molecular substrates modulating in these 
interactions are not completely understood.  Current data demonstrating glial 
contributions to sleep regulation suggests further investigation is warranted as these 
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cells may be critical mechanistic components of sleep and immune interactions 
throughout the lifespan.  Future studies might aim to address the immune 
consequences of inhibiting glial activity and how this relates to sleep alterations.  
Also, the mechanisms driving dysregulation of sleep and central immune responses 
in aging are not well defined.  Answering these, and other questions, is necessary 
before network components of sleep-immune interactions and their role in healthy 
aging may be fully elucidated. 
 
Acknowledgements 
This work was supported in part by the National Institutes of Health, grants 
NS025378, NS031453 and HD036520 to JMK and AG041827 and MH064843 to 
MRO. 
  
126 
 
 
 
 
 
Figure A.1: Glial modulation of sleep and immune interactions. Cellular activity 
causes ATP release into the extracellular space via neurotransmission and 
gliotransmission. Extracellular ATP induces rapid effects once metabolized to 
adenosine by ectonucleotidases such as CD39 and CD73. Adenosine binds to 
purine type 1 receptors like the A1R to modulate EEG slow wave activity and 
NREMS, as well as local neuroinflammation and excitotoxicity. Slower effects of 
extracellular ATP occur through direct activation of purine type 2 receptors such as 
the P2X7R prominently expressed on microglia. P2X7R activation induces 
processing and release of cytokines including, but not limited to, IL-1β and TNFα. 
Cytokines subsequently act on their respective receptors to activate transcription 
factors like nuclear factor-κB (not shown) which modulates neuroinflammation, 
physiological and pathological sleep, and gene transcription of receptors such as the 
A1R, AMPA, and the AMPA subunit GluR1. This overly simplified schematic focuses 
on the featured topics of this mini-review, and thus, not all cellular and molecular 
components are fully represented. AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid receptors; GluR1, glutamate receptor 1.  
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APPENDIX B 
 
 
LIPOPOLYSACCHARIDE-INDUCED BEHAVIORAL RESPONSES OF MICE 
EXPRESSING INTERLEUKIN-1 RECEPTOR 1 OR TUMOR NECROSIS FACTOR 
RECEPTOR 1 SELECTIVELY ON NEURONS OR ASTROCYTES 
 
 
INTRODUCTION 
At the time we engineered the NSE-IL1R1 and GFAP-IL1R1 mice, we 
concurrently developed transgenic counterparts for tumor necrosis factor α (TNF) 
that express TNF receptor 1 (TNFR1) only in the central nervous system and 
selectively on neurons (NSE-TNFR1) or astrocytes (GFAP-TNFR1).  Similar to 
interleukin-1β (IL-1), TNF is a pro-inflammatory cytokine that mediates sleep and 
multiple aspects of the innate immune response.  Febrile responses and symptoms 
of sickness, such as sleep-wake alterations, decreased feeding and water intake, 
loss of body weight, and social withdrawal can also be induced by central 
administration of TNF (Bluthe et al., 1994, Dantzer, 2004, Opp, 2005, Chida and 
Iwakura, 2007).  TNF exerts its effects through two receptors: TNF p55 (TNFR1) and 
TNF p75 (TNFR2).  However, most biologic activity of TNF is mediated via TNFR1 
which is expressed on neurons and astrocytes (Vandenabeele et al., 1995). 
Prior to deciding to direct the focus of this dissertation to IL-1 contributions to 
sleep and immune responses, we ran a pilot study aimed at determining the effects 
of lipopolysaccharide (LPS) on symptoms of sickness in wild type (B6129SF2/J), 
NSE-IL1R1, NSE-TNFR1, and GFAP-TNFR1 mice.  Founders for GFAP-IL1R1 mice 
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were being generated at the time of this study, and are not included in the following 
dataset.  The transgenes for all transgenic mice were expressed on a genetic 
background lacking endogenous expression for both IL1R1 and TNFR1.  Below is a 
brief summary of the pilot study that demonstrates the relative contributions of 
neurons and astrocytes to behavioral response to LPS as modulated by IL1R1 and 
TNFR1. 
 
METHODS 
Adult male B6129SF2/J (n = 4), NSE-IL1R1 (n = 3), NSE-TNFR1 (n = 4), and 
GFAP-TNFR1 (n = 3) mice were surgically instrumented with 
electroencephalographic (EEG) electrodes to determine arousal state.  EEG data 
were obtained via a lightweight, tethered swinging arm system.  Mice were housed 
with running wheels in recording chambers maintained at 29 ± 1°C under a 12:12 h 
light:dark cycle.  All mice received pyrogen-free saline (PFS; 0.2 ml) intraperitoneally 
(i.p.) at dark onset.  The next day mice were challenged at dark onset with LPS (0.4 
mg/kg; i.p.).  EEG, wheel running, body weight, and food and water intake data were 
collected for 24 h following each injection. 
 
RESULTS AND DISCUSSION 
LPS suppressed rapid eye movement sleep (REMS) and increased non-
REMS (NREMS) of B6129SF2/J, NSE-IL1R1, and NSE-TNFR1 mice, whereas 
GFAP-TNFR1 mice exhibited no sleep alterations in response to LPS (Figure B.1).  
LPS also decreased wheel running activity of B6129SF2/J, NSE-IL1R1, and NSE-
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TNFR1 animals (Figure B.2).  However, wheel running was preserved in GFAP-
TNFR1 mice following challenge with LPS.  Finally, LPS decreased body weight and 
food and water intake of B6129SF2/J, NSE-IL1R1, and NSE-TNFR1 mice (Figure 
B.3). Body weight, feeding, and drinking was maintained in GFAP-TNFR1 mice after 
LPS.  These data suggest that selective expression of TNFR1 on astrocytes is not 
sufficient for behavioral immune responses to systemic challenge with LPS. 
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Figure B.1:  Effects of intraperitoneal injection of PFS and LPS on percentage of 
time spent in REMS and NREMS for B6129SF2/J, NSE-IL1R1, NSE-TNFR1, and 
GFAP-TNFR1 mice.  Values are hourly averages expressed as means ± S.E.M.  
PFS (0.2 ml; i.p.) was injected at dark onset followed by LPS (0.4 mg/kg; i.p.) at dark 
onset the next day. EEG was recorded and sleep states determined. The filled and 
open bars on the X-axis indicate dark and light periods of the light-dark cycle, 
respectively. 
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Figure B.2:  LPS-induced alterations in wheel running activity of B6129SF2/J, NSE-
IL1R1, NSE-TNFR1, and GFAP-TNFR1 mice.  Values are hourly and 12 h averages 
expressed as means ± S.E.M.  PFS (0.2 mL; i.p.) was administered at dark onset 
followed by LPS (0.4 mg/kg; i.p.) at dark onset the next day. Running wheel activity 
was recorded. The filled and open bars on the X-axis indicate dark and light periods 
of the light-dark cycle, respectively. 
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Figure B.3:  Body weight, feeding, and drinking responses to LPS of B6129SF2/J,  
NSE-IL1R1, NSE-TNFR1, and GFAP-TNFR1 mice.  Values are 24 h averages 
expressed as means ± S.E.M.  PFS (0.2 mL; i.p.) was administered at dark onset 
followed by LPS (0.4 mg/kg; i.p.) at dark onset the next day. Body weight, food 
intake, and water intake data were collected daily.   
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